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Abstract
Ginseng has played a vital role in traditional Chinese medicine for thousands of years. There
are 22 cultivars of ginseng including North American ginseng (Panax quinquefolius) and
Asian ginseng (Panax ginseng). The use of North American ginseng has increased
dramatically and there is a strong need to understand its immunomodulatory effects. This is
because the majority of current research focusing on the Asian ginseng variant. Human
peripheral blood mononuclear cells (PBMC) were used to test the immunomodulatory
properties of 3 North American ginseng extracts, COLD-FX® and deglycosylated individual
ginsenosides. Microarray analysis of PBMC exposed to the aqueous ginseng extract was used
to determine the induced transcriptional profile. The aqueous ginseng extract induced a Th1
transcriptional profile likely by modulating the MAPK (ERK-1/2), PI3K, p38 and NF-κB
signalling pathways. The high molecular weight polysaccharides of North American ginseng
induced the production of pro-inflammatory cytokines and decreased the adaptive T cell
response to superantigen. These responses were antagonized by deglycosylated ginsenosides
that also antagonized the induction of pro-inflammatory cytokines in LPS stimulation of
PBMC. Based on these results, ginseng polysaccharides and

ginsenosides are

immunomodulatory, inducing a Th1 transcriptional profile. Our results may assist the
development of optimized ginseng preparations with targeted immunomodulatory activity.

Keywords
Ginseng; Panax quinquefolius; Human; Ginsenoside; Polysaccharide; Peripheral Blood
Mononuclear Cells; Immunomodulation; Microarray; Cytokines
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Introduction

1.1 Human Immune System
The human immune system is a vital part of human life as it protects the body against
harmful pathogens and internal damage. To do this, the immune system recognizes
pathogens, eliminates them and whenever possible generates immunological memory.
The immune system is specific to recognize pathogens and pathogen-infected cells.
However, the ability to discriminate self non-self can be broken down, resulting in
autoimmune diseases such as multiple sclerosis.
The cells of the immune system are all derived from a pluripotent hematopoietic stem cell
in bone marrow. Common lymphoid progenitor cells give rise to B cells, T cells and
natural killer cells (NK), while common myeloid progenitor cells are the source of
neutrophils, eosinophils, basophils, mast cells and monocytes 1. All these cell types play
an important role in various immune responses, ensuring the optimal function of the
immune system.
Immune responses can be divided into two broad classifications, innate and adaptive. The
innate immune responses are the first line of defense against an invading pathogen as
they begin immediately after the pathogen enters the body. The innate immune responses
include: the anatomical barriers that aim to prevent a pathogen from entering the body,
the recognition of pathogens by Pattern Recognition Receptors (PRR) expressed in
macrophages, neutrophils and DC and activation of the complement system, that all work
together to eliminate the pathogen. Finally the innate immune response helps control the
spread of pathogens. The ability of the innate immune system to respond immediately to
pathogen invasion is accomplished by sensing what is considered a pathogen through
detecting pathogen associated molecular patterns (PAMPs) 2.
The adaptive immune system on the other hand is characterized by its ability to recognize
pathogens in a specific manner and the ability to generate immunological memory. The
main cell types of the adaptive immune system are B and T cells that have clonotypic
receptors for billions of different antigens present in pathogens. These single specificity
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receptors allow for the differentiation between pathogens and the specific recognition of
pathogens. However, in order for a pathogen to be recognized by a B or T cell it must be
phagocytosed and processed by an antigen-presenting cell (APC). Once a T cell has been
presented with its appropriate antigen it will differentiate into effector and memory cells.
The effector cells will begin to aid in the removal of the pathogen while memory cells
will remain in the body long after the infection has been cleared. Due to the coordination
required to initiate an adaptive immune response, these responses are not as immediate as
the innate immune response and usually take one to two days to begin. However, once
memory cells are present in the body, the adaptive immune response can begin much
faster if the body is reinfected with the same pathogen.

1.1.1 Anatomical Barriers
Anatomical barriers are the first line of defense against invading pathogens. These
barriers are composed of an epithelial cell layer that lines the surfaces of the body that are
exposed to the outside. The external epithelial layer, such as skin, provides an incredible
challenge for invading microbes containing commensal microflora to prevent the
colonization of skin by bacteria. It is only when the epithelial layer is damaged that
pathogens can enter the body. As a result, the majority of invading pathogens will enter
through the internal epithelial layers in the lung or gut. These epithelial layers use
defense mechanisms such as mucus and antimicrobial peptide secretions, pH changes and
the presence of commensal microbiota 2.

1.2 Innate Immunity
Once a pathogen passes the anatomical barriers, the innate immune system is responsible
for clearance of the pathogen. This is, in part, accomplished by the presence of preformed
soluble anti-microbial molecules and enzymes in the blood and bodily fluid, which
recognize common features of many pathogens such as defensins, cathelicidins and
lysozyme 3. The complement system, a complex system of plasma proteins that target
bacteria and viruses for lysis or phagocytosis by macrophages and other cells, is also an
important innate immune response 4. These soluble molecules work in conjunction with
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the macrophages, neutrophils and DC of the immune system to contain and eliminate the
pathogen.
If bacteria enter the body, phagocytic cells that patrol tissue for incoming pathogens will
recognize them. Macrophages are one of the phagocytic cell types present in all tissues.
Macrophages mature from monocytes when they exit the blood and enter the tissue
through a process known as extravasation. Neutrophils are short-lived cells that are
commonly found in the blood and not the tissue. Neutrophils are recruited to a tissue
infected by a pathogen and clear the pathogen mainly by phagocytosis 5, 6.
Alternatively, the clearance of viral infections can also use different cell types and
mechanisms. Viral infections induce the production of the anti-viral cytokines interferonα (IFN-α) and IFN-β. Plasmacytoid dendritic cells have been shown to be particularly
important for producing large amounts of interferon to aid in the antiviral response 2.
IFN-α and IFN-β are both ligands to a common interferon receptor which, upon
activation, induces many antiviral mechanisms including the production of proteins that
interfere with viral replication, increased expression of co-stimulatory molecules on
macrophages and DCs and the activation of NK cells 7.
Innate immune responses do not provide long-term immunological memory. This is only
accomplished by the initiation of an adaptive immune response.

1.2.1 Pro-inflammatory Immune Response
Inflammation is a very important component to pathogen clearance and plays a vital role
in many physiological processes from repair mechanisms to facilitating of the initiation
of an adaptive immune response. The three major roles of inflammation are to recruit
effector cells to the site of infection, induce local blood clotting and promote pathogen
clearance 2. The inflammatory response typically begins minutes after the initial pathogen
is detected and can last for many days.
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In order to initiate the pro-inflammatory response, activated macrophages secrete
molecules such as prostaglandins, leukotrienes and platelet-activating factor. These
molecules begin the vasodilation processes. Pathogen entry and detection also activates
the kinin system. The kinin system is an enzymatic cascade ultimately resulting in the
production of bradykinin to increase vascular permeability 8. Activated macrophages
secrete tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) which vasodilates
surrounding blood vessels, reducing the speed of blood flow and increasing the
expression of adhesion molecules such as P-selectin, LFA-1, V-CAM-1 and ICAM-1 9.
Vasodilation of the surrounding blood vessels results in increased blood flow to the
infected area and increased chance for neutrophils and NK cells to bind to the adhesion
molecules and extravate into the tissue. TNF-α increases vascular permeability to allow
more fluid to flow out of the blood vessels and into the tissue, bringing with it plasma
proteins such as those in the complement cascade 2. Finally, clotting occurs in the small
blood vessels around the site of infection to prevent the spread of the pathogen. Clotting
of the surrounding blood vessels occurs through activation of the coagulation cascade 10.
Another important feature to the inflammatory response is the use of chemoattractant
cytokines known as chemokines. These small proteins direct the movement of cells
toward the source of chemokine through changes in the cytoskeleton and adhesiveness of
the cell. The major role of chemotaxis in the inflammatory response is the movement of
cells out of the blood and into the site of infection. For example CCL2 attracts most
monocytes to the site of infection and induces them to become tissue macrophages 2. This
is similar to the role of CXCL8 that induces neutrophils to leave the blood and enter the
site of infection

2

. Not only do chemokines direct the movement of important

inflammatory cells to the site of infection, they also promote extravasation. Chemokines
alter the leukocyte integrins to facilitate stable binding with endothelial adhesion
molecules such as P-selectin, LFA-1, V-CAM-1 and ICAM-1, allowing the macrophages,
neutrophils and other cells to enter the site of infection 2. There are over 50 known
chemokines, some of which target immune cells 2. Cytokines and chemokines work
together to recruit immune cells to the site of infection.
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Another way of activating pro-inflammatory responses is through the complement
system. This plasma system is composed of more than 30 proteins that are produced by
the liver in the absence of infection and circulate in the blood in their inactive form 2.
These inactive proteases become active upon enzymatic cleavage typically by another
complement protein. The interaction of the 30 complement proteins form the three major
arms of complement activation, the classical pathway that requires the binding of
complement component 1 (C1) to the pathogen surface or to an antibody already bound
to the pathogen surface, the alternative pathway that can be activated by C3 activation
and the lectin pathway that uses mannose or ficolin-binding proteins to recognize
carbohydrate structures on the surface of pathogens 2. The lectin pathway, similar to
macrophages and neutrophils use proteins that function as PRR to recognize PAMP. The
three pathways converge on the key activation step of the complement system, C3
cleavage into C3a and C3b by C3 convertase. C3b is the main effector molecule of the
system and when it is bound covalently to the surface of the pathogen it acts as an
opsonin, activating complement phagocytes to engulf the pathogen 2. C3b can also bind
to the C3 convertase on lectin and antibody mediated complement cells to form C5
convertase. C5 convertase forms C5a and C5b, C5b activates the formation of a
membrane-attack complex leading to lysis of the pathogen 2. The byproducts C3a and
C5a act on endothelial cells to induce inflammation by constriction of smooth muscle,
increasing vascular permeability and inducing the synthesis of adhesion molecules 2. C3a
and C5a also activate mast cells in mucosal epithelial layers to release TNF-α that also
causes similar pro-inflammatory effects 2. The complement system is another way that
the pro-inflammatory system can be activated and perpetuated.
Pro-inflammatory immune responses, regardless of how they were initiated, must also be
controlled. One of the mechanisms is through the use of anti-inflammatory cytokines
such as IL-10 and transforming growth factor β (TGF-β). IL-10 reduces the intensity of
pro-inflammatory immune responses by reducing T cell activation, IL-2 production,
expression of major histocompatibility complex (MHC) and co-stimulatory molecules 2.
TGF-β participates in decreasing pro-inflammatory responses by targeting T cells,
blocking their cytokine production and killing mechanisms 2. These cytokines are
characteristic of many regulatory cell subsets such as regulatory T cells (Tregs). These
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cells are important for attenuation of the pro-inflammatory response

11

. However, many

other cell types can secrete IL-10 including Th1, Th2, Th17 and B cells 2.

1.2.2 Lipopolysaccharide Recognition
Lipopolysaccharide (LPS) is a structural component of the outer cell wall of gramnegative bacteria. It is an endotoxin and produces strong immune responses in mammals.
Each LPS molecule has three separate domains, namely the O-antigen, the core and the
lipid A domains 3. The O-antigen is a repetitive glycan polymer that makes up the
outermost portion of LPS. The longer the O-antigen polymer chains are, the more
difficult it is to penetrate the bacteria 12. The core domain can contain many compounds
including phosphates and amino acids. However it will always contain an oligosaccharide
that is used to bind the lipid A domain

12

. Lipid A is a phosphorylated glucosamine

disaccharide with multiple hydrophobic fatty acids attached and is responsible for the
toxicity of LPS

13

. The fatty acids attached to lipid A anchor LPS into the bacterial

membrane 14.
The LPS receptor is found on the surface of DC and macrophages and is composed of 3
subunits, cluster of differentiation 14 (CD14), Toll like receptor 4 (TLR-4) and MD-2.
These three clusters work together to recognize and signal the presence of LPS, CD14 is
a GPI-anchored protein and requires TLR-4 to signal, while TLR-4 requires the accessory
protein MD-2 for correct trafficking to the cell surface as well as for LPS recognition 3.
The lipid domains of LPS bind to the hydrophobic cup in MD-2 of one TLR-4 MD-2
complex

15

. The binding of LPS to one complex recruits a second TLR-4 and MD-2

complex that further binds the LPS lipid and carbohydrate domains resulting in a TLR-4
dimerization and activation of downstream signaling cascades

16

. Some LPS can break

free from the cell wall and be picked up by an LPS binding protein. In this case, LPS is
transferred from the LPS-binding protein to CD14 on the surface of monocytes and
macrophages 17. LPS binding to CD14 still results in the dimerization of TLR-4 and MD2 and the activation of the same downstream signaling cascades.
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TLR-4 dimerization brings together the cytoplasmic toll/interleukin-1 receptor (TIR)
domains of TLR-4 to interact with TIR domains of certain adaptor molecules. Based on
the TLR-4 ligand, there are two possible signaling cascades used, the myeloid
differentiation factor 88 (MyD88)-dependent pathway is used for recognition of bacterial
pathogens, while the MyD88-independent pathway is used for recognition of viral
pathogens. In the MyD88-dependent pathway, TLR-4 uses the adaptor molecules MyD88
and MyD88 adaptor-like (MAL), which recruit IL-1 receptor activated kinase (IRAK1)
and IRAK4

18

. The activation of IRAK4 is required for the function of the MyD88-

dependent pathway and IRAK4 inactivation leads to a rare immunodeficiency resulting in
recurrent bacterial infections 18. Ultimately, the MyD88 dependent cascade results in the
activation and translocation of nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) into the nucleus to induce the transcription of pro-inflammatory cytokine
genes such as IL-1β, IL-6 and TNF-α

19

. Alternatively, in the MyD88-independent

pathway, TLR-4 uses the adaptor molecules TIR domain-containing adaptor-inducing
IFN-β (TRIF) and TRIF-related adaptor molecule (TRAM). These adaptor molecules
ultimately induce the downstream phosphorylation of the interferon regulatory
transcription factor 3 (IRF3), inducing the expression of IFN-β 5, 20, 21.

1.3 Adaptive Immunity
While there is significant cross talk between the innate and adaptive immune systems, the
adaptive immune system is still very distinct. The main function of the adaptive immune
system is to recognize pathogens in a specific manner and generate immunological
memory to those pathogens. The cells responsible for these functions are the B and T
cells. B and T cells have clonotypic receptors to billions of different antigens

22

. When

naïve B and T cells are presented with an antigen that they can bind, they will undergo
proliferation and differentiate into effector cells and memory cells.
The major function of B cells is to produce antibodies and contribute to immunological
memory. B cells are formed in the bone marrow and migrate to the spleen to mature.
During development a B cell receptor (BCR), membrane bound immunoglobulin, is
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formed on all B cells, each composed of two heavy chains and two light chains 2. Both
heavy and light chains have a variable region, used to recognize the antigen, and a
constant region that determines the function of the antibody. Genetic recombination of
the variable (V), diversity (D) and joining (J) gene segments known as VDJ for the heavy
chain and VJ recombination for the light chain variable regions are used to create a vast
number of BCRs each with a unique specificity 23. There are also five different constant
regions encoded on separate heavy chain C-region genes. IgM, IgD, IgG, IgE and IgA
differ in the number of disulfide bonds, the presence or absence of a hinge region, the
number and location of sugar groups, the number of domains in the constant region as
well as the function of the antibody 2. Once a B cell comes into contact with its specific
antigen, it will then differentiate into plasma cells that secrete large amounts of soluble
BCR known as antibodies, with the exact same specificity as the BCR 2. Activated B
cells will also form memory B cells, which are long lived cells that are able to respond
more quickly if the pathogen is reencountered at a later time.
T cells also recognize antigens in a specific way and create immunological memory.
However, T cells do so in a very different way from B cells. T cell antigen recognition is
controlled by transmembrane glycoproteins known as MHC molecules. These molecules
contain a cleft on their surface to which a peptide antigen can be bound and recognized
by a T cell. TCRs recognize features of the MHC molecule and the peptide antigen,
known as MHC restriction 2. Like B cells, T cells are also formed in the bone marrow but
mature in the thymus. During development, they use similar gene rearrangement
processes to develop a vast repertoire of T cell receptors (TCRs). Similar to the BCR, the
TCR also has a heavy and light chain, TCRα and TCRβ respectively, each with a variable
region used to specifically recognize pathogens

24

. TCRα undergoes Vα and Jα gene

recombination while the TCRβ undergoes Vβ Dβ Jβ gene recombination 24. Subsequent to
TCR formation, T cells undergo positive and negative selection in the thymus to remove
auto-reactive T cells and subsequently differentiate them into CD4+ or CD8+ T cells. The
TCR is made up of two polypeptide chains, the majority of which are α and β chains 25.
These heterdimers are connected by a disulfide bond and recognize the majority of T cell
antigens

25

. There are also γ and δ polypeptide chains that appear in a substantially

smaller number of T cells

25

. The γ:δ heterodimers recognize their antigens directly and
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does not require them to be presented in MHC molecules 25. Because of this γδ T cells are
considered to be innate-like immune cells 2.
Naïve CD4+ and CD8+ T cells circulate through the peripheral lymphoid tissue in search
of their antigens. An adaptive immune response begins when a DC or any other type of
professional antigen-presenting cell (APC) presents an antigenic peptide to a T cell with a
TCR specific to that peptide. In CD8+ cells that peptide would be presented on a MHC
class I molecule, whereas CD4+ T cells recognize longer peptides presented on MHC
class II molecules. The APC must also present T cells with appropriate co-stimulatory
signals such as CD80/CD86, to prevent cells from becoming unresponsive or anergic 2. T
cells also have mechanisms to prevent the recognition of self-peptides and subsequent
death of self cells. For example, in antigen presentation of a pathogen, B7 binds CD28.
However, when self peptides are presented, there is commonly a lack of CD28 on the cell
surface. Therefore, the absence of CD28 signals that the presented peptide is a self
peptide 26. The activation of the TCR ultimately results in the activation of NF-AT, NFκB and MAPK. The activation of these signalling molecules will eventually result in the
transcription of the IL-2 gene and ultimately IL-2 production leading to T cell
proliferation.
Activated CD4+ and CD8+ T cells begin dividing into approximately 1000 clonal effector
cells in the next three to five days 2. Effector CD8+ T cells are cytotoxic T cells that will
go on to kill virally infected cells. Likewise, CD4+ effector cells are T helper (Th) cells
that go on to provide additional signals to other cells in the immune system

27

. Some

effector T cells will migrate to the site of infection and others will stay in the lymphoid
tissue to activate B cells 2. A subset of these antigen-experienced cells will persist as
memory cells. Like memory B cells, their function is to decrease the time required to
initiate an adaptive immune response when the same antigen is encountered.
The adaptive immune system is concerned with specific recognition of pathogens and
creating immunological memory for these pathogens. However, the adaptive immune
system could not function properly without the APCs and more specifically the DCs of
the innate immune system.
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1.3.1 Th1, Th2 and Th17 T cell responses
Upon antigen recognition, T cells differentiate into effector cells. CD8+ T cells become
cytotoxic T cells that kill infected cells, while CD4+ T cells can differentiate down
distinct pathways that generate subsets with different effector functions. There are
currently four different effector subsets that are well defined: T helper 1 (Th1) cells, Th2
cells, Th17 cells and T follicular helper (TFH) cells. The identification of these subsets is
based on the profile of cytokine production resulting from activation.
Naïve T cells differentiate into the different effector subsets (e.g. Th1, Th2, Th17 and TFH)
depending on the cytokine microenvironment. Th1 cells are the result of differentiation in
the presence of IL-12 and IFN-γ 28, 29. This is because IFN-γ and IL-12 activate the janus
tyrosine kinase (JAK) and signal-transducing activators of transcription (STAT)
intracellular pathways to alter gene transcription. Initially, IFN-γ is produced by activated
NK cells as the IFN-γ gene in CD4+ T cells is turned off 2. In the presence of IFN-γ and
IL-12, STAT1 is activated and induces the expression of the transcription factor T-bet,
which switches on the IFN-γ gene and the IL-12 receptor

30

. Once this occurs cells are

committed to the Th1 pathway. IL-12 can then be induced by STAT4 to promote the
differentiation and expansion of Th1 committed cells 2. Th1 effector cells will produce a
large amount of IFN-γ when they encounter antigen, which further signals the
differentiation of more Th1 cells.
The effector function of Th1 cells is unique from other linages. Th1 cells are involved
primarily with the killing of intracellular bacteria in macrophages. Under normal
conditions, macrophages phagocytose and degrade bacteria in the phagolysosome.
However, some bacteria evolve mechanisms to persist intracellularly in macrophages and
evade the macrophage killing mechanisms. In this situation, Th1 cells interact with such
macrophages to activate their anti-microbial activity to kill the resident bacteria 2. Th1
effector T cells also play an important role in the killing of virus infected cells by
orchestrating the differentiation of CD8+ T cells into cytotoxic cells 27. Th1 cells increase
the activation of naïve CD8+ T cells by secreting IL-2 to increase the expression of the
co-stimulatory signals, B7 and 4-1BBL on dendritic cells 2. B7 and 4-1BBL provide
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additional co-stimulatory signals to CD8+ T cells to aid in differentiation into cytotoxic
cells 2.
The differentiation of a naïve CD4+ T cell down the Th2 pathway is dependent on the
presence of IL-4 during maturation. This is because IL-4 activates the STAT6 receptor on
T cells promoting the expression of GATA3 31. Th2 T cells are functionally distinct from
Th1 in that Th2 cells control parasite infections by promoting responses of eosinophils,
mast cells and IgE antibodies. Specifically, IL-4, IL-5, IL-9 and IL-13 are secreted from
T cells and required to switch B cells to produce IgE antibodies 32.
Finally, Th17 cells arise in the presence of IL-6 and TGF-β and the absence of IL-4 and
IFN-γ during maturation 33. Th17 cell development involves an initial production of IL-21
to activate STAT3, a transcription factor required for Th17 cell production 30. RORγT is
the transcription factor expressed by differentiated Th17 cells and enables them to
produce IL-17 in the absence of IFN-γ and IL-4 34. Th17 T cells protect against infection
by extracellular bacteria and fungi through stimulating the neutrophil response that helps
clear pathogens.
Another function of CD4+ T cells is to provide help to B cells to produce antibodies. This
is because effector T cells secrete the required cytokines to induce isotype switching
resulting in different effector functions of antibodies. For example, of the characteristic
Th2 cytokines IL-4 and IL-5, IL-4 increases the class switching of antibodies to IgG4 and
IgE, while IL-5 increases class switching to IgA

35

. While IFN-γ and IL-2 the

characteristic Th1 cytokines increase the class switching of antibodies to IgG2a and IgG3
35

.

1.3.2 Staphylococcus aureus Enterotoxin E Recognition
S. aureus is a gram-positive bacteria that can live as a commensal in the nose and skin. It
causes a wide variety of skin and soft tissue infections as well as more invasive diseases
leading to bacteremia and sepsis

36

. S. aureus strains have been shown to produce up to

20 seriologically distinct superantigens. Superantigens are small, secreted pyrogenic
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exotoxins, with a molecular weight between 20 – 28 kDa

37

. Superantigens have two

domains, the A domain contains a C-terminal β-motif and a central α-helix region, while
the B domain contains the N-terminal oligosaccharide binding domain 38.
Superantigens have a distinct method of binding to both the MHC complex and the TCR
in order to activate a large number of T cells. Normal T cell antigens bind MHC
molecules in the peptide-binding groove. Alternatively, superantigens do not bind this
groove and instead bind to the outside surface of the alpha or beta chains of some MHC
class II molecules

36

. In this way, superantigens can activate up to 20% of all T cells,

which is substantially more than a normal T cell antigen

39

. Due to the non-specific

activation of T cells induced by superantigen stimulation, the resulting response is not
specific to the pathogen. Instead, the broad activation of T cells results in large scale
production of IL-2, an inducer of T cell proliferation, and ultimately suppresses the
adaptive immune response as a consequence of activation-induced cell death resulting in
a cytokine storm and systemic toxicity 40.
S. aureus can also cause a number of skin and systemic infections including impetigo,
staphylococcal scalded skin syndrome, toxic shock syndrome (TSS), osteomyelitis and
endocarditis 41. The wide array of diseases induced by this single pathogen is in part due
to the fact that its virulence factors have a number of different targets including
neutrophil chemotaxis, inhibition of complement mediated opsonization, disruption of
epithelial layers and inactivation of antimicrobial peptides 42. S. aureus also has a number
of virulent superantigens that cause diseases. For example, TSS can be a life-threatening
disease that is induced by the toxic shock syndrome toxin 1 (TSST-1) of S. aureus

42

.

TSST-1 also causes a similar but much less sever disease in neonates known as neonatal
toxic shock syndrome-like exanthematous disease 42. The superantigens of S. aureus can
also be used as a tool to activate and study T cell activation in the laboratory. Due to the
specific nature of T cell activation through conventional means, it is very difficult to
purify an antigen specific population of T cells. Therefore, superantigen stimulation can
be used as a model of T cell activation.
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1.4 Introduction to North American Ginseng
1.4.1 The History of Ginseng
Generations of people have used natural products in medicine, cosmetics, dyes and
beverages to promote health and longevity. Among these, ginseng is considered the most
prized plant in Asia and is growing in popularity worldwide

43

. The first known

documentation of ginseng use was in the commentary book, “Shennong Bencao Jing
(Shennong’s Herbal)” by Tao Hongjing and written in the Liang Dynasty, 502-557 A.D.
44

. It was based on the findings of Chinese Emporor Yan, considered to be the father of

natural medicine for his role in the discovery of many medicinal plants 45.
The discovery of ginseng in North America did not occur until 1709 when Father Jartoux,
a Jesuit missionary in China, wrote a letter describing the ginseng root and its properties
to Father Lafitau in St. Louise, Canada, near Montreal. In 1714 Lafitau recognized the
description of ginseng as a plant that he often saw in the forest. At that time North
American ginseng grew only in southern Canada and the eastern United States

43

. Once

farmers knew of the proposed health benefits of ginseng based on traditional Chinese
medicine, an intense effort was made to cultivate the prize crop. It was not until 1897
when George Stanton discovered the importance of growing ginseng in the shade, that
this effort succeeded and cultivation became a reality 46.
North American and Asian ginseng are part of the Panax genus along with 10 other
ginseng species

47

. There are also 12 other ginseng-like species classified into other

genuses. However, the Panax genus, including Asian ginseng (P. ginseng) and North
American ginseng (P. quinquefolius) are considered true ginseng as they produce
ginsenosides, unique to the ginseng plant. Due to the unique growing conditions ginseng
requires and the wide spread over-harvesting of ginseng in the early 1900’s North
American ginseng is currently only grown in southwestern Ontario and the state of
Wisconsin. In order to help prevent the further over harvesting of North American
ginseng, in 1973 P. quinquefolius was listed in Appendix II of the Convention on
International Trade in Endangered Species of Wild Fauna and Flora (CITES).
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Accordingly, the federal government must approve all exports of ginseng, deeming that
export will not be detrimental to the survival of the species in the wild 48.
In recent years there has been an increased number of people using ginseng in North
America. Due to the readily available supply of North American ginseng and the high
costs of Asian and other types of ginseng, North Americans have been consuming North
American ginseng more than any other type. However, there is a major lack of scientific
evidence to validate the claims traditionally attributed to Asian ginseng for North
American ginseng.

1.4.2 Ginseng Plant
Ginseng is a perennial plant that is often difficult to grow as it is highly affected by soil
moisture, temperature changes and soil composition

49

. However, even under ideal

conditions, ginseng is still a very slow growing plant and takes 4-6 years before it can be
harvested. When fully mature, ginseng plants produce edible red berries and large leaves
but it is its extensive underground root systems that is typically harvested 50.
The harvest of ginseng roots is labor intensive and kills the entire plant. Once ginseng is
harvested, it has to undergo significant processing for its commercial use including
heating and drying. The type of ginseng produced is dependent on the age of the ginseng
plant at the time of harvest and the type of post-harvest processing it undergoes

51

. For

example, if the roots are harvested less than 4 years after they were planted then they are
called fresh ginseng and do not require processing. White ginseng roots are harvested
between 4 - 6 years after planting and they are peeled and dried. Lastly, red ginseng is
harvested 6 years after planting and it is steamed at 100 °C and dried

43

. The various

methods of processing ginseng roots have been shown to change the content of the root
as well as it’s the composition of ginsenosides 52, 53.
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1.5 Ginseng Components
While the root of the ginseng plant is the part of the plant most commonly used, all of the
compounds present in the root are present throughout the plant in different concentrations
including the leaves, stems and berries. The five compounds of interest with respect to
ginseng are the peptides, fatty acids, polyacetylenes, ginsenosides and polysaccharides.
The peptides and fatty acids of ginseng have not been isolated for study as
immunomodulatory

compounds.

However,

extensive

research

using

isolated

polyacetylenes, ginsenosides and polysaccharides has been carried out each yielding very
different results.

1.5.1 Polyacetylene Compounds
Polyacetylenes are long organic polymer chains with a (C2H2)n repeating structure that
can be found in many plant species including carrots (Daucus carota L.)

54

. There are

seven major polyactylenes that are common across many species of ginseng including
panaxynol, ginsenoyne –A, panaxydol, 10-methoxy heptadeca-1-ene-4, 6-dyne-3, 9-diol,
panaxytriol, panaxyne and ginsenoyne – C. The ratio of these compounds changes based
on the growth conditions of the ginseng as well as its post-harvest processing. However,
many of these compounds have been shown to play a key role in ginsengs anti-tumor and
anti-cancer properties. For example, in a mouse xenograft model panaxydol was shown to
decrease the toxic side effects associated with standard cancer treatment such as weight
loss, peripheral neuropathy and hematotoxicity 47. Furthermore, panaxydol has also been
shown to preferentially induce apoptosis in human cancer cells through a caspasedependent and mitochondrial-mediated response

55

. Finally, panaxytriol has been shown

to cause significant cytotoxicity and inhibit DNA synthesis in multiple tumor cell lines 56.

1.5.2 Ginsenosides
Ginsenosides have been claimed to be the active ingredients of ginseng for many years.
Ginsenosides are low molecular weight steroidal saponins unique to the Panax genus.
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The two most common groups of ginsenosides are the protopanaxadiol and
protopanaxatriol ginsenosides. These groups differ in their 4-trans ring steroidal
backbone

57

. In order to create unique ginsenosides from the protopanaxadiol backbone,

sugar moieties are attached to the β-OH at carbon 3 and/or carbon 20. Likewise, unique
ginsenosides are created by the addition of sugar groups to the α-OH at carbon 6 and/or
the β-OH at carbon 20 of the protopanaxatriol backbone 7. The differential addition of
sugar side chains has resulted in the presence of over 100 unique ginsenosides. These
sugar groups are deglycosylated by intestinal bacteria such as Bacteroides sp.
Bifidobacterium sp.

59

, Fusobacterium sp.

Leuconostoc paramesenterioides

61

60

, Lactobacillus delbrueckii

61

58

,

, and

into their biologically active forms upon ingestion.

The types of ginsenosides present in extracts are also very important to the biological
function of that extract, as different ginsenosides appear to have different effects on the
body. There are many factors that affect the content of ginsenosides present in ginseng
roots including age, root dry weight, soil fertility, light, population size and location 62.
The majority of ginseng research has focused on ginsenosides as the active components.
A large amount of this research has been carried out using specific ginsenosides to
determine their immunomodulatory function. For example, ginsenosides have repeatedly
been shown to have anti-tumor properties 63-65. Ginsenosides also have strong effects on
diabetes, for example, Rb2 inhibits gluconeogenesis through the AMPK pathway 66. Rb3
and other ginsenosides have also been shown to have mood enhancing effects 67, 68.

1.5.3 Polysaccharides
The saccharide component of ginseng includes oligosaccharides, pectic polysaccharides
and starches

69

. Preliminary data indicates that some of these saccharides originate from

the cell wall of ginseng plant cells. However, not all polysaccharides present in the
extracts were detected using their methods

70

. The remaining unidentified

polysaccharides may or may not be part of the cell wall of ginseng plant cells or other
organelles in the ginseng plant. Many saccharides have been identified in both Chinese
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and North American ginseng extracts to be important in the immunomodulatory response
of ginseng including ginsan

71

, panaxans, arabinogalactans

72

, rhamnogalacturonan II 73,

galactose, arabinose, rhamnose, and glucose, as well as monosaccharides fucose and
mannose 74.
While significantly less research has been done on polysaccharides than ginsenosides,
polysaccharides are emerging as the new immunomodulatory compounds of ginseng. For
example, ginseng polysaccharides have been key in advancing the use of ginseng as an
adjuvant. This is because complex polysaccharide extracts have been shown to induce
more IgG production compared to control 75. Ginseng has also been shown to have strong
bacteriocidal activity against many bacteria including S. aureus

76

. Finally,

polysaccharides have also been shown to induce the formation of regulatory T cells
through the activation of FoxP3 resulting in less severe experimental autoimmune
encephalomyelitis 77.

1.5.4 Composition of North American Ginseng Extracts
As previously discussed, the majority of ginseng research has been done using single
purified compounds of ginseng. However, this does not represent how ginseng is
currently being used. In order to mimic the current uses of ginseng worldwide, we used
an aqueous, polysaccharide and ethanol extract in our studies. These extracts most closely
mirror the use of ginseng in tea and soup, candy and alcoholic beverages such as wine
and whiskey respectively. Due to the chemical properties inherent in the solvents
required to make the three extracts, the composition of each extract is vastly different.
The ethanol extract is composed of a complex mixture of ginsenosides

78

. While the

aqueous extract contains the same complex mixture of ginsenosides, it also contains the
polysaccharides of the ginseng root as well

78

. Finally, the polysaccharide extract is

prepared by precipitating out the polysaccharides from the aqueous extract, therefore it is
only composed only of the polysaccharides in the aqueous extract 78.
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1.5.5 Composition of COLD-FX®
COLD-FX® is a major reason why the use of North American ginseng has increased in
recent years as it is composed of over 80% poly-furanosyl-pyranosyl-saccharides,
isolated from a North American ginseng aqueous extract

79

. Therefore, COLD-FX® is

used as a control for my work as it is a commercially prepared product made by Afexa
Life Science Inc. This polysaccharide family is isolated from the roots of North American
ginseng using an aqueous extract and further precipitation by ethanol, similar to the
preparation of our polysaccharide ginseng extract.
The major claim of COLD-FX® is that it can decrease the frequency and severity of cold
and flu symptoms. This claim was substantiated in a clinical trial of immune competent
elderly people, where taking COLD-FX® for four months reduced the relative risk of
respiratory symptoms of cold and flu by 48-55% 80, 81. These results may be in part due to
the COLD-FX® induced maturation of monocyte derived dendritic cells

82

, increased

presence of memory T cells and the induction of prototypical Th1 cytokines including IL12 and IFN-γ which have been reported by other groups 79.

1.6 Experimental Rational, Hypothesis and Specific Aims
Ginseng has been thought to regulate the immune system since its discovery thousands of
years ago. However, the majority of ginseng research has used Asian ginseng and
focused on specific compounds including single ginsenosides or polyacetylenes. These
compounds have been used to determine their effects in narrow experimental conditions,
disregarding their effects on the immune system as a whole. Furthermore, the use of
individual purified compounds is not representative of how ginseng is currently being
used. Ginseng is currently being used in the form of ginseng extracts. These complex
solutions contain many different compounds isolated from ginseng. By using North
American ginseng extracts to stimulate PBMC the results represent more accurately
represent the effect of ginseng, in the way it is currently being used, on the human
immune system. This is required to fully understand the effects of one of the most widely
used natural medicine products in the world.
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While the search for the active immunomodulatory compounds of ginseng proceeds, it is
important to use a biologically relevant system to determine the immunomodulatory
effects. For this research PBMC were used as they closely reflect systemic effects due to
blood bioavailability. The majority of previous ginseng research has been done using
leukemia cell lines that represent only single cell types of the immune system50, 57, 78.
These cells are often much larger than average immune cells and have differential
expression of receptors as compared to healthy PBMC. By using PBMC for our research
we negate the altered cell size and changes in receptor expression often found in these
cells.
Our lab became interested in defining the immune effects of North American ginseng. To
do this we used three extracts, the aqueous, polysaccharide and ethanol North American
ginseng extracts, in order to mimic how ginseng is currently consumed. Preliminary data
confirmed the induction of the pro-inflammatory cytokines IL-6, IL-1β and TNF-α by
North American ginseng aqueous and polysaccharide extracts as well as COLD-FX® in
human PBMC

83

. Our lab also determined that the compounds responsible for this

activation were water-soluble compounds found in the aqueous and polysaccharide North
American ginseng extracts with a molecular weight greater than 77,000 Da. These
compounds induced the greatest amount of phosphorylation of the AKT, NF-κB and
ERK-1/2 signaling molecules in PBMC when compared to compounds of molecular
weight less than 77,000 Da and the aqueous or polysaccharide extracts 83. This lead to the
idea that ginseng extracts are immunomodulatory, however further work was required to
determine the exact responses which were affected and what the active compounds were.
It also remained unclear whether or not there is any antagonism between the different
compounds in the three extracts tested.

1.6.1 Hypothesis
Our preliminary data suggest that ginseng has an immunomodulatory effect on the innate
and adaptive immune responses of PBMC. Therefore, I am proposing that the
modulatory effects of ginseng extracts on human innate and adaptive immune
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responses are mediated by water-soluble compounds with a molecular weight
greater than 77 kDa found in the aqueous and polysaccharide ginseng extracts. In
order to address this hypothesis I will address the innate and adaptive immune responses
in the presence of ginseng, by determining the effects of ginseng treatment on pro- and
anti-inflammatory cytokine production in response to different stimuli. I will then use
cytokine production as a read out for the effect of ginseng on representative innate and
adaptive immune responses, induced by LPS or SEE respectively. I will then define the
transcriptional profile induced by the aqueous extract through the use of microarray
analysis, followed by heat mapping and ingenuity pathway analysis. In addition, I will
fractionate the aqueous and polysaccharide extracts to isolate the fractions containing the
active immunomodulatory compounds of ginseng. I will do this by using differential
fractionation with ultra centrifugal filter units and using cytokine production as a read out
for immunomodulatory capacity. Finally, I will characterize the antagonistic effects of
ginsenosides on the effect of the aqueous or polysaccharide ginseng extracts.

1.6.2 Specific Aim One: To establish the effects of ginseng extracts on
innate and adaptive immune responses of human PBMC.
In order to understand the effects of North American ginseng extracts on PBMC, we
began by looking at the effects of ginseng stimulation on the induction of pro- and antiinflammatory cytokines. We chose IL-6, IL-1β and TNF-α as pro-inflammatory cytokines
and IL-10 as a representative anti-inflammatory cytokine. As expected from the
literature, ginseng induced a large production of pro-inflammatory cytokines by PBMC.
However, ginseng treatment also induced the production of a large amount of IL-10. The
magnitude of cytokine production was not equal between the extracts, as the
polysaccharide and aqueous extracts consistently induced the greatest cytokine
production with minimal or no cytokine production induced by the ethanol extracts. In
order to ensure that this effect was not specific to the ginseng produced at one single
farm, we used three different ginseng extracts from seven different ginseng farms across
southwestern Ontario. LPS contamination was ruled out through polymyxin B treatment.
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Therefore, the induction of cytokines was based on properties of the compounds in the
extracts themselves.
To determine if the pro-inflammatory cytokines were derived from monocytes or another
cell population, we isolated two monocyte subsets and compared the level of IL-6
production with PBMC. CD14+CD16- and CD14+CD16+ monocytes were used as they
have different potencies of antigen presentation on the cell surface, with CD14+CD16+
monocytes having a higher potency of antigen presentation than CD14+CD16- monocyte
84

. When PBMC were treated with the aqueous or polysaccharide North American

ginseng extracts or COLD-FX®, there was no significant difference in the IL-6
production by either of the two monocyte populations. However, both monocyte cell
populations produced significantly less IL-6 then PBMC treated with the aqueous or
polysaccharide ginseng extracts. Interestingly, there was no difference in the IL-6
production between PBMC and either of the monocyte cell populations tested when
treating cells with COLD-FX®. Therefore, it appears that the complex mixture of
polysaccharides present in both the aqueous and polysaccharide extracts are able to
activate multiple cell types including B cells, T cells, NK cells, monocytes, macrophages,
DC and basophils, while the single polysaccharide family present in COLD-FX® can only
activate monocytes.
To define the effects of ginseng extracts on the innate and adaptive immune responses,
we used LPS and SEE to induce characteristic responses respectively. After costimulation of PMBC with LPS and any of the three ginseng extracts it was determined
that none of the extracts have any effect on the IL-6 response to LPS. Production of IL-6
was used as a readout of cell activation, and this trend was observed across a variety of
LPS and extract concentrations. Alternatively, when PBMC were co-cultured with
various concentrations of the superantigen SEE and one of the three ginseng extracts,
using IL-2 as a readout of T cell activation, the aqueous and polysaccharide ginseng
extracts decreased the adaptive immune response to SEE. These results were also
confirmed with extracts from all seven different farms of ginseng.
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Since the induction of pro- and anti- inflammatory cytokines, as well as the suppression
of IL-2 production in response to SEE was ubiquitous across all seven farms. Extracts
from farm three gave the greatest extract yield and were therefore the only extracts used
in further experiments.

1.6.3 Specific Aim Two: To define the transcriptional profile induced
by the aqueous ginseng extract.
To determine the transcriptional profile induced by the aqueous ginseng extract on human
PBMC, microarray analysis was performed on two independent donors. After exclusion
of genes with less than a 2 fold change, there were 104 commonly up-regulated genes
between the two donors and 53 commonly down-regulated genes. Interestingly, IFN-γ the
characteristic TH1 cytokine was the top up-regulated gene, while formyl peptide receptor
3 (FPR3) was the most down-regulated gene. When the changes in gene expression were
mapped using heat mapping, there were obvious similarities between the gene expression
changes of both donors after treatment with the North American ginseng aqueous extract.
Using Ingenuity Pathways analysis (IPA) the top 20 up-regulated genes were used as the
basis to form a network of the pathways that are most perturbed by transcriptional
changes at those genes. This analysis led to the inferred modulation of the MAPK (ERK1/2), PI3K, p38 and NF-κB pathways in response to treatment of PBMC with the aqueous
ginseng extract. This network, along with the rest of the microarray data, presents a
profile of immunomodulation, specifically of a TH1 response by signaling through the
MAPK (ERK-1/2), PI3K, p38 and NF-κB pathways.
In order to confirm the up-regulation of IFN-γ, IL-12p40, IL-12p70 and IL-23 observed
in microarray analysis, we used ELISA analysis to quantify protein. Similar to previous
results, the aqueous ginseng extract induced significant amounts of IFN-γ, IL-12p40, IL12p70 and IL-23 while the ethanol ginseng extract only produced significant amounts of
IL-12p40. However, the polysaccharide extract only induced significant levels of IFN-γ
IL-12p40 and IL-23. Contrary to previous results COLD-FX® did not induce significant
amounts of any of the four cytokines tested. Similarly, to confirm the result of CD14
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down-regulation observed in microarray analysis flow cytometry was used. Both COLDFX® and the aqueous ginseng extract resulted in a significant decrease in surface
expression of CD14.

1.6.4 Specific Aim Three: To perform a preliminary isolation and
characterization of the active immunomodulatory compounds of
ginseng.
To further investigate the active immunomodulatory compounds of ginseng, the aqueous
and polysaccharide extracts were fractioned using differential fractionation with ultra
centrifugal filter units. The aqueous and polysaccharide extracts were chosen as they
induced a much greater response in cytokine production, as well as were the only extracts
to have an effect on the SEE response. When PBMC were treated with the fractions of
the aqueous and polysaccharide extracts, the only fraction which was able to come close
to recapitulating the IL-6 response of the extracts themselves was the greater than 100
kDa fraction. Furthermore, the other four fractions did not induce a similar profile of
cytokine production; the production induced by these fractions was much less than that of
the extracts themselves. This result was reflected in both the aqueous and polysaccharide
extracts. Moreover, the ability of the fractions to induce the production of other cytokines
including IL-1β and TNF-α was measured also, with similar trends as the IL-6 data
presented.
In order to further understand the effect of the greater than 100 kDa fraction in its
capacity to immunomodulate, we determined the effect of the fractions compared to the
aqueous and polysaccharide ginseng extracts on the SEE response. PBMC were cotreated with SEE and the different ginseng fractions from the aqueous and polysaccharide
extracts, as well as the extracts themselves. Similar to the previously observed profile,
only the greater then 100 kDa fraction had a similar effect on the SEE response as the
extracts.
Ginsenosides, low molecular weight saponin molecules unique to GS, have historically
been considered the active immunomodulatory ingredients of ginseng. However, since
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this conflicted with our previous results, we obtained 11 purified, biologically active
ginsenosides and two ginsenoside mixtures to test their immunomodulatory capacity. CY, C-Mc and Gyp LXXV (pure) induced the pro-inflammatory cytokine IL-1β, while CY, C-Mc, Gyp LXXV (pure), C-O and Gyp XVII (mixture) induced significant IL-6
production in PBMC. However, contrary to the effects of the ginseng extracts, all of the
13 ginsenosides tested decreased IL-6 production in response to LPS. Alternatively, none
of the ginsenosides tested had a biologically relevant effect on the response to SEE.
The observation that ginsenosides down-regulate the LPS response while the aqueous and
polysaccharide extracts had no effect on the LPS response, implied the existence of a
possible antagonistic effect between ginsenosides and the other components of the
extracts, in particular the polysaccharides in the ginseng extracts. To determine if this
was the case, PBMC were co-stimulated with ginsenosides and the aqueous or
polysaccharide extract. While none of the ginsenosides tested antagonized IL-1β induced
by the polysaccharide ginseng extract, C-Mc1, C-K, C-Mc, C-O, C-Y, Gyp XVII (pure),
F2, PPD, Rg3 and Rh2 antagonized the IL-1β induced by the aqueous extract.
The antagonism of the aqueous ginseng extract prompted us to further characterize the
effects of ginsenosides on PBMC treated with either the aqueous or polysaccharide
extract when challenged with LPS or SEE. All of the 13 ginsenosides tested except Gyp
LXXV (mixture), Gyp XVII (mixture) and Gyp LXXV (pure) antagonized the IL-6
production of PBMC treated with LPS, the aqueous ginseng extract and a ginsenoside,
when compared to PBMC treated with LPS and the aqueous ginseng extract.
Furthermore, there was no meaningful biological difference between PBMC treated with
LPS, the polysaccharide ginseng extract and a ginsenoside when compared to PBMC
treated with LPS and the polysaccharide ginseng extract. Similarly, when the IL-2
production of PBMC treated with SEE, the aqueous ginseng extract and ginsenosides was
compared to that of PBMC treated with SEE and the aqueous ginseng extract, Gyp XVII
(mixture), F2, Rh2 were the only ginsenosides that did not result in an increase in IL-2
production. While, when PBMC were treated with SEE, the polysaccharide ginseng
extract and a ginsenoside was compared with the IL-2 production of PBMC treated with
SEE and the polysaccharide ginseng extract, only Gyp XVII (mixture) and Gyp XVII
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(pure) resulted in an increase in IL-2 production. Based on our results it is likely that the
antagonism of ginseng polysaccharides by ginsenosides occurs at a common step
downstream of the binding receptor for each compound. This also has major implications
for the use of ginseng extracts and it may be more beneficial to use single compounds of
ginseng based on the desired outcomes. For example, ginseng polysaccharides may be
more beneficial for increasing pro-inflammatory cytokine secretion, while ginsenosides
decrease the immune response to LPS.
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2

High Molecular Weight Polysaccharides are Key
Immunomodulators in North American Ginseng Extracts:
Characterization of the Ginseng Induced Genetic Signature in
Human Primary Immune Cells

2.1 Statement of Contribution
This manuscript was submitted to the Journal of Ethnopharmacology on December 8
2011 with authorship as follows, Holly R. Lemmon, Jane Sham, Luan Chau and Joaquín
Madrenas. As first author my scientific contributions to this manuscript were completing
all the data on the induction of cytokines IL-6, IL-1β, TNF-α, IL-10, IFN-γ, IL-12P40,
IL12-P70 and IL-23 by PBMC and monocytes. I also completed all of the data on the
effect of the North American ginseng extracts on LPS and SEE as well as all of the
fractionation data including the induction of IL-6, and the effect of the fractions on the
LPS and SEE responses of PBMC.

2.2 Abstract
Ethnopharmacological relevance: Ginseng (GS) has played a pivotal role in traditional
Chinese medicine for thousands of years. Its use has become increasingly popular in
North America, in part due to the many claims of its immune-enhancing properties. The
immunopharmacology of the North American variety of GS and its extracts is needed to
substantiate these claims.
Materials and Methods: Human peripheral blood mononuclear cells were exposed to
different North American GS extracts and microarray analysis was performed. The
profile of cytokine response to GS extracts was established by ELISA, and Ingenuity
Pathway Analysis was used to identify potential signaling pathways responsible for the
transcriptional profile induced by GS. Fractionation of the aqueous and polysaccharide
extracts was done to determine the molecular weight of the active immune modulatory
ingredient(s).

36

Results: We found that GS induced a transcriptional profile of immunomodulation
characterized by a net Th1 immune response, with up-regulation of multiple proinflammatory cytokines (e.g., IFN-γ, IL-23A and IL-6) and down-regulation of TGF-β,
IL-13 and the LPS co-receptor CD14. Ingenuity Pathway Analysis (IPA) revealed that
the MAPK (ERK-1/2), PI3K, p38 and NF-κB cascades were key signalling pathways
through which GS may trigger its immunomodulatory action. Furthermore, induction of
such an immunomodulatory signature was recapitulated with the high molecular weight
polysaccharides found in aqueous and polysaccharide GS extracts.
Conclusions: Based on our results, we conclude that high molecular weight
polysaccharides in North American GS aqueous and polysaccharide extracts likely
modulate the MAPK (ERK-1/2), PI3K, p38 and NF-κB signalling pathways in PBMC
resulting in the induction of a Th1 transcriptional profile. Our results may assist in
optimizing GS-mediated immunomodulation and focus the search for compounds in GS
extracts with specific immunomodulatory activities.

2.3 Introduction
Ginseng (GS) is the name given to several species of perennial plants that produce berrylike flowers and fleshy roots. The two most commonly recognized species of GS are the
Asian GS Panax ginseng and the North American GS Panax quinquefolius 1, 2. Asian GS
is regularly consumed as an ingredient in tea, alcoholic beverages or candy 3. GS has also
been an important part of traditional Chinese herbal remedies for thousands of years

1, 2

due to claimed health benefits such as enhancement of immunity, stress relief and
prevention of aging 4, 5.
The current use of GS extends beyond Asia. In 2002, 4–5% of Americans aged 45–64
years of age, accounting for approximately 13 million individuals, used GS as a herbal
supplement 6. In North America, GS has become the second-highest selling herbal
supplement; in 2000, GS had gross retail sales of nearly $62 million 7. In Canada, 17–
32% of patients with cardiovascular disease reported use of alternative supplements and
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6% of those using herbs reported GS use 8. Additionally, GS is the 10th most used herbal
supplement in HIV patients, accounting for 34% of individuals studied 9. With growing
interest in the Western market for herbal medicine, an increasing amount of attention has
focused on North American GS 10.
Despite the wide use of North American GS, the mechanism of action and the effects of
specific extracts from this root remain mostly unknown. The biological effects of GS
have generally been attributed to ginsenosides, low molecular weight saponins found in
GS 2. For example, ginsenosides have been shown to have anti-tumour and oxidativestress prevention properties 5, 11-14. However, it is unclear if the immune effects of GS are
due to ginsenosides or to other components in GS. In particular, polysaccharides isolated
from GS, such as poly-furanosyl-pyranosyl-saccharides and monosaccharide have been
claimed to have immune-enhancing effects 15, 16, justifying the use of preparations such as
COLD-FX®, which contains 80% of poly-furanosyl-pyranosyl-saccharides from North
American GS 15, and marketed to prevent upper respiratory tract infections 17.
To explore the immunomodulatory capacity of distinct North American GS extracts, we
examined the profile of gene expression induced on human peripheral blood mononuclear
cells (PBMC) by water-soluble GS (P. quinquefolius) fractions (i.e. aqueous extracts of
GS equivalent to tea-like preparations of GS). We found that aqueous GS extracts induce
a transcriptional profile characterized by an enhanced innate and adaptive Th1 proinflammatory immune response - a profile corroborated at the protein level. These
changes were induced mostly by high molecular weight fractions of polysaccharide
extracts of North American GS.

2.4 Materials and Methods
2.4.1 Cells
Informed consent from all individuals was obtained in compliance with the Office of
Research Ethics at the University of Western Ontario. Ficoll-Hystopaque density gradient
centrifugation was used to isolate human PBMC from healthy volunteers. Cells were
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cultured in RPMI-1640, supplemented with 10% FCS, 1% L-glutamine, 1%
penicillin/streptomycin, 1% MEM non essential amino acids, 1% 1M Hepes and 1%
sodium pyruvate.

2.4.2 Preparation of North American GS extracts
Roots of Panax quinquefolius were collected from 7 different farms in Southwestern
Ontario, Canada. Samples were ground and soaked three times for five hours in water or
an ethanol/water (75/25, v/v) solution at 40 °C. The solutions were then filtered and
excess solvent was removed in a rotavaporizer under vacuum at 45 °C. Powdered
aqueous extracts (10 g) were dissolved in 10 mL of distilled water. Four volumes of 95%
ethanol were added to the solution in order to precipitate crude polysaccharides.
Polysaccharide precipitate was collected by centrifugation (3000 rpm for 10 minutes) and
freeze dried at -50 °C under reduced pressure. The crude polysaccharide (1 g) was redissolved in distilled water (10 mL) and treated with Sevag reagent (1:4 nbutanol:chloroform, v/v, 40 mL) to remove proteins. After re-precipitation by ethanol and
freeze-drying, a final polysaccharide fraction was obtained. The content of these extracts
has been previously described
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. These different types of North American GS extracts

and their fractions were used throughout this work and are referred to as GS extracts or
corresponding fractions. Lipopolysaccaride (LPS) contamination of GS extracts was
ruled out by the Limulus test and further ensured by treatment with Polymyxin B.

2.4.3 Preparation of GS extracts fractionated according to molecular
weight
Twenty mg of powdered GS extracts were dissolved in 1 mL of colourless media. Five
hundred µL of GS extract at 20 mg/mL was placed in a 100 kDa Millipore Centrifugal
Filter Unit (Billerica, MA). The filtrate was then put into centrifugal filter units with
sequentially lower molecular weight cut offs (50 kDa, 30 kDa and 10 kDa). 50µL of
colourless media was used to wash each filter and remove any precipitate.
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2.4.4 Reagents
COLD-FX was purchased from commercial sources (Afexa Life Sciences Inc.
Mississauga, ON). According to manufacturer’s description, it contains CVT-E002, a
proprietary ChemBioPrint® (CBP®) product of greater than 80% poly-furanosylpyranosyl-saccharides extracted by an aqueous method from Panax quinquefolius.
Staphylococcal aureus enterotoxin E (SEE) was purchased from Toxin Technologies
(Sarasota, FA). Escherichia coli lipopolysaccharide (LPS), phorbol 12-myristate 13acetate (PMA) and ionomycin were purchased from Sigma-Aldrich (St. Louis, MO).

2.4.5 Functional assays
Human PBMC (2 x 105 cells) in 200 µL of media per well in 96-well U-bottom plates
(Nunc, Rochester, NY) were stimulated for 20 hours with increasing concentrations of up
to 200 µg/mL of GS extracts or COLD-FX, by themselves or in the presence of LPS or
SEE. Quantification of IL-1β, IL-6, IL-10, TNF-α, IFN-γ, IL-12p40, IL-12p70, IL-23 and
IL-2 was performed using human OptEIA™ ELISA kits (BD Biosciences, San Diego,
CA).

2.4.6 Monocyte Isolation
CD14+ monocyte isolation was performed using MACS human monocyte positive
isolation kit (Miltenyi Biotec, Auburn, CA). CD14+CD16+ monocyte isolation was
performed using EasySep negative selection kit (Stemcell Technologies, Vancouver,
BC). Monocytes were then counted and plated at 50,000 cells in 200 µL of media per
well in 96-well U bottom plates and were stimulated with increasing concentrations of
GS extracts or COLD-FX for 20 hours.

2.4.7 Microarray Analysis
Total RNA from cells of two independent donors was isolated using a Qiagen kit
(Qiagen, Valencia, CA) and used to generate cDNA. cDNA samples were hybridized to
the Affymetrix GeneChip Human Gene 1.0 sense target Array (Affymetrix, Santa Clara,
CA). Expression levels were converted to fold changes by comparing expression levels
between treatment and control sample arrays (Partek Incorporated, St. Louis, MO). Genes
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with a fold change less than 2 were filtered and eliminated from analysis. Profiled
clusters of genes were identified and correlated to functional effects using Partek
software (Partek Incorporated).

2.4.8 Ingenuity Pathway Analysis (IPA)
Affymetrix microarray data was analysed using the IPA program that identifies
relationships, mechanisms, functions, and pathways of biological relevance that are most
significantly perturbed in a given dataset (Ingenuity Systems, Redwood City, CA).

2.4.9 Flow cytometry
FITC-labelled anti-CD14 antibodies were used to assess CD14 expression on the cell
surface by flow cytometry. FITC-labelled anti-mouse IgG1κ antibodies were used as
isotype controls.

2.4.10

Statistical Analysis

Graphpad Prism (Graphpad Instat Software Inc., San Diego, CA), was used to perform
ANOVA with post-hoc Bonferroni tests to determine the statistical significance of
differences among groups. Probability values of P < 0.05 were considered significant.

2.5 Results
2.5.1 Aqueous and polysaccharide extracts of North American GS
induce a broad profile of cytokine production
To start identifying the immunomodulatory effects of GS we first measured the effect of
the different North American GS extract formulations on immune cell activation, using
induction of cytokine production as a read-out. We found that GS extracts induced the
production of IL-6, IL-1β, TNF-α and IL-10 by human PBMC in a dose-dependent
manner (Fig. 2.1). However, there was a marked difference in the magnitude of this effect
between different types of GS extracts. Aqueous and polysaccharide extracts induced
significantly more cytokine production than the ethanol extract (P < 0.001) (Fig. 2.1).
COLD-FX, used as a control, induced a similar profile of cytokine production as the
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aqueous and polysaccharide extracts. The cytokine response induced by GS extracts was
corroborated using extracts prepared from seven different GS farms (Fig. 2.1).
Furthermore, this response was not due to LPS contamination because no endotoxin was
detected with the Limulus test and the cytokine response was resistant to polymyxin B
(data not shown).
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Figure 2.1
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Figure 2.1. - Cytokine response of human PBMC to aqueous, polysaccharide and
ethanol GS extracts from 7 different North American GS farms. Human PBMC were
stimulated with increasing concentrations of COLD-FX (top row graphs) or of aqueous
(▲), polysaccharide (▼) and ethanol ( ) extracts derived from the roots of North
American GS plants obtained from 7 different farms for 20h. IL-1β, IL-6, TNF-α and IL10 in the supernatants were measured by ELISA. Data represent mean and standard
deviation of triplicates, and are representative of 3 independent experiments. Differences
between responses to aqueous or polysaccharide extracts vs. ethanol extracts were
significant as determined by two-way ANOVA (P < 0.001).
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To determine the contribution of monocytes to the pro-inflammatory IL-6 response of
PBMC to GS, two monocyte subsets were isolated. CD14+ monocytes make up the
majority of monocytes, approximately 90% in peripheral blood, the other 10% being the
highly pro-inflammatory CD14+CD16+ monocytes, which have a higher potency of
antigen presentation than preparations of monocytes based on CD14+ expression only 19.
Interestingly, we found no significant difference between the amounts of IL-6 produced
by either monocyte subset in response to GS extracts (Fig. 2.2a and 2.2b) but both
monocyte subsets produced significantly less (P < 0.05) IL-6 in response to the aqueous
or polysaccharide extract than PBMC with the same treatments. Interestingly, such a
difference was lost when using COLD-FX® (Fig. 2.2C), suggesting that the IL-6 response
to the GS extracts involves a different set of mechanisms.
Next, we tested whether the different GS extracts could inhibit the response to LPS. We
observed that neither the GS extracts (polysaccharide, aqueous or ethanol) from 7
different GS farms nor COLD-FX® caused any change in the immune response to LPS as
measured by IL-6 production (Fig. 2.3). This lack of effect was observed across a wide
range of LPS and extract concentrations, suggesting that it was not due to saturation of
the LPS response.
To further characterize the immune properties of GS extracts we examined the effects of
these extracts on the T cell response to superantigens. Superantigens such as SEE activate
up to 20% of peripheral blood T cells as illustrated by an increase in IL-2 production
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(Fig. 2.4). The addition of aqueous or polysaccharide GS extracts during SEE-induced T
cell activation resulted in significant (P < 0.05) down regulation of the IL-2 response
(Fig. 2.4). This effect was not significant for the ethanol extracts. Furthermore, such an
activity was consistently seen across extracts from the seven GS farms tested.
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46

Figure 2.2
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Figure 2.2. – IL-6 responses of PBMC, CD14+ monocytes and CD14+CD16+
monocytes to GS extracts and COLD-FX. Human PBMC ( ), CD14+ monocytes
(▲) and CD14+CD16+ monocytes (●) from the same donor were stimulated with
increasing concentrations of (A) aqueous GS extract, (B) polysaccharide GS extract and
(C) COLD-FX for 20h. IL-6 accumulation in culture supernatants were measured by
ELISA. Data represent mean and standard deviation of triplicates. Differences between
the responses of CD14+ and CD14+CD16+ monocytes were significantly different from
those of PBMC as determined by two-way ANOVA *: P < 0.05, **: P < 0.01, ***: P <
0.001.
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Figure 2.3

49

Figure 2.3. - Aqueous, polysaccharide and ethanol GS extracts do not inhibit the
innate immune response to LPS. Human PBMC were stimulated with increasing
concentrations of LPS alone ( ) or in the presence of 150 µg/mL aqueous (▲),
polysaccharide (▼) and ethanol ( ) GS extracts from 7 different farms or COLD-FX
(●) for 20h. IL-6 accumulation in culture supernatants was measured by ELISA. Data
represent mean and standard deviation of triplicates.
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Figure 2.4
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Figure 2.4. - Aqueous and polysaccharide GS extracts down-regulate the IL-2
response to S. aureus superantigens (SEE). Human PBMC were stimulated with
increasing concentrations of SEE alone ( ) and with 150 µg/mL of aqueous (▲),
polysaccharide (▼) and ethanol ( ) GS extracts from 7 different farms or COLD-FX
(●) for 20h. IL-2 accumulation in culture supernatants was measured by ELISA. Data
represent mean and standard deviation of triplicates. Differences between GS extracts or
COLD-FX and the SEE alone group were significantly different as determined by oneway ANOVA. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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2.5.2 Transcriptional profile induced by aqueous extracts of North
American GS.
To broadly characterize the response of PBMC to an aqueous GS extract we performed
microarray analysis of this response. After exclusion of genes with a less than a 2 fold
change over baseline, we found that 104 genes were up-regulated and 53 genes were
down-regulated in response to the aqueous GS extract. Bioinformatics analysis of these
genes revealed a transcriptional profile of immunomodulation (Tables 2.1 and 2.2). IFN-γ
gene, coding for the primary Th1 cytokine, was found to be the most up-regulated gene in
response to GS. Formyl peptide receptor 3 (FPR3) was the most down-regulated gene.
An overwhelming number of the regulated genes coded for cytokines, chemokines, or
were genes required for proper immune function. These results were replicated in
genetically unrelated donors and broad similarities in the heat map profile were detected
in those donors (data not shown).
To control for the quality of the DNA microarray results, we examined the changes at the
protein level for some of the most significantly regulated genes. As predicted by the
microarray data, we found that IFN-γ, IL-12p40 and IL-23 were up-regulated by COLDFX®, and the aqueous and polysaccharide GS extracts compared to ethanol GS extract
(Fig. 2.5). CD-14 was identified in the microarray to be down-regulated and this downregulation was confirmed at the protein level by flow cytometry. After 30 minutes (data
not shown) and 4 hours of incubation with the aqueous GS extract or COLD-FX®, there
was a significant decrease (P < 0.05) in expression levels of cell surface-CD14, measured
by mean fluorescents intensity (MFI) (Fig. 2.6).
Next, we studied the molecular relationship of the top 20 up-regulated genes identified in
the microarray analysis using Ingenuity Pathway Analysis (IPA). IPA generated a
molecular network identifying which biological pathways were most greatly perturbed by
those genes (Fig. 2.7). This resulted in the identification of several signalling molecules
as being involved in the immune response to an aqueous GS extract including p38
MAPK, PI3K (complex), NF-κB (complex) and ERK 1/2.
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Table 2.1: Up-regulated Genes in Human PBMC in response to an Aqueous GS
Extract
Rank

Gene
Symbol

NCBI Reference
Sequence ID

Description

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

IFNG
MMP1
MMP10
CXCL9
CXCL10
CSF2
CSF3
IL1F9
IL24
IL23A
IL20
F3
IFIT1
MIR146A
IL6
INHBA
TNF
IFIT2
RNF152
TNFSF15
RHCG
STOM
IFIT3
HERC5
RTP4
MIR221
GJB2
CXCL2
OAS3
RSAD2
MX1

NM_000619
NM_002421
NM_002425
NM_002416
NM_001565
NM_000758
NM_172220
NM_019618
NM_006850
NM_016584
NM_018724
NM_001993
NM_001548
NR_029701
NM_000600
NM_002192
NM_000594
NM_001547
NM_173557
NM_005118
NM_016321
NM_004099
NM_001031683
NM_016323
NM_022147
NR_029635
NM_004004
NM_002089
NM_006187
NM_080657
NM_002462

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

MIR155
IL1R1
GEM
IFI35
C13orf29
USP18
TFPI2
CD69
USP18
DHX58
SPINK1
CXCL11
CFB
BST2
PNPT1
IFI44
GPRC5A
CFB
OAS1
PRIC285

NR_030784
NM_000877
NM_005261
NM_005533
NR_027701
NM_017414
NM_006528
NM_001781
NM_017414
NM_024119
NM_003122
NM_005409
NM_001710
NM_004335
NM_033109
NM_006417
NM_003979
NM_001710
NM_016816
NM_001037335
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HSH2D

NM_032855

interferon, gamma
matrix metallopeptidase 1 (interstitial collagenase)
matrix metallopeptidase 10 (stromelysin 2)
chemokine (C-X-C motif) ligand 9
chemokine (C-X-C motif) ligand 10
colony stimulating factor 2 (granulocyte-macrophage
colony stimulating factor 3 (granulocyte)
interleukin 1 family, member 9
interleukin 24, transcript variant 1
interleukin 23, alpha subunit p19
interleukin 20
coagulation factor III (thromboplastin, tissue factor)
interferon-induced protein with tetratricopeptide repeats 1
microRNA 146a (MIR146A), microRNA
interleukin 6 (interferon, beta 2)
inhibin, beta A
tumor necrosis factor
interferon-induced protein with tetratricopeptide repeats 2
ring finger protein 152
tumor necrosis factor (ligand) superfamily, member 15
Rh family, C glycoprotein
stomatin, transcript variant 1
interferon-induced protein with tetratricopeptide repeats 3
hect domain and RLD 5
receptor (chemosensory) transporter protein 4
microRNA 221, microRNA
gap junction protein, beta 2, 26kDa
chemokine (C-X-C motif) ligand 2
2'-5'-oligoadenylate synthetase 3, 100kDa
radical S-adenosyl methionine domain containing 2
myxovirus (influenza virus) resistance 1, in interferoninducible protein p78 (similar to mouse)
microRNA 155, microRNA
interleukin 1 receptor, type I
GTP binding protein overexpressed in skeletal muscle
interferon-induced protein 35
chromosome 13 open reading frame 29
ubiquitin specific peptidase 18
tissue factor pathway inhibitor 2 (TFPI2
CD69 molecule, transcript variant 1
ubiquitin specific peptidase 18
DEXH (Asp-Glu-X-His) box polypeptide 58
serine peptidase inhibitor, Kazal type 1
chemokine (C-X-C motif) ligand 11
complement factor B
bone marrow stromal cell antigen 2
polyribonucleotide nucleotidyltransferase 1
interferon-induced protein 44
G protein-coupled receptor, family C, group 5, member A
complement factor B
2',5'-oligoadenylate synthetase 1, 40/46kDa
peroxisomal proliferator-activated receptorA interacting
complex 285
hematopoietic SH2 domain containing

Fold Change
Range of
Upregulation
53.2 – 55.9
14.3 - 16.7
12.5 – 13.0
7.5 – 23.1
5.6 – 11.0
4.9 - 5.3
5.2 – 8.6
5.2 – 23.5
4.7 – 8.5
4.2 – 6.7
2.8 - 3.8
3.7 – 18.2
3.7 – 15.6
3.6 – 5.5
3.5 – 5.1
3.5 – 20.2
3.3 – 3.4
3.3 – 8.0
2.0 - 3.2
3.2 – 8.5
3.2 – 9.1
2.9 - 3.1
3.1 – 10.2
3.1 – 11.1
3.1 – 4.8
3.0 – 3.9
3.0 – 9.4
3.0 – 5.0
3.0 – 9.6
3.0 – 17.2
3.0 – 8.1
3.0 – 6.7
2.9 – 8.2
2.9 – 4.0
2.8 – 5.8
2.7 – 3.1
2.7 - 14.7
2.7 - 5.4
2.7 – 3.2
2.7 – 11.4
2.6 – 5.5
2.6 – 4.5
2.6 – 17.1
2.6 – 13.5
2.6 – 3.6
2.6 – 7.7
2.6 – 8.6
2.5 – 4.9
2.5 – 12.7
2.5 – 6.2
2.5 – 3.9
2.5 – 2.1
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53
54
55
56
57
58
59
60
61
62
63
64
65
66
67

STAT2
LY6E
DDX58
PGAP1
ZBP1
HERC6
PMAIP1
GBP5
CXCL3
PARP9
IFI44L
PRKD2
IFIH1
ISG20
LIF

NM_005419
NM_002346
NM_014314
NM_024989
NM_030776
NM_017912
NM_021127
NM_052942
NM_002090
NM_031458
NM_006820
NM_016457
NM_022168
NM_002201
NM_002309

68
69
70
71
72
73

IRF7
PRF1
SLC38A5
TM4SF1
CFB
RASGRP3

NM_004031
NM_005041
NM_033518
NM_014220
NM_001710
NM_170672

74

SLC4A10

NM_001178015

75
76
77
78
79
80
81
82
83
84
85

GNG2
AREG
PPM1K
AREG
MX2
EPSTI1
APOL1
TXN
CCNA1
EREG
MOV10

NM_053064
NM_001657
NM_152542
NM_001657
NM_002463
NM_001002264
NM_145343
NM_003329
NM_003914
NM_001432
NM_020963

86
87
88

PARP14
DDX60
CMPK2

NM_017554
NM_017631
NM_207315

89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104

RGS1
TDRD7
CCL3
OASL
TMEM140
OAS2
SLFN12L
PML
FNIP2
DUSP5
STAP1
CCL20
LAMP3
CCRN4L
CHRNA6
TNFRSF9

NM_002922
NM_014290
NM_002983
NM_003733
NM_018295
NM_002535
NM_001145027
NM_033240
NM_020840
NM_004419
NM_012108
NM_004591
NM_014398
NM_012118
NM_004198
NM_001561

signal transducer and activator of transcription 2, 113kDa
lymphocyte antigen 6 complex, locus E
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
post-GPI attachment to proteins 1
Z-DNA binding protein 1 (ZBP1),
hect domain and RLD 6
phorbol-12-myristate-13-acetate-induced protein 1
guanylate binding protein 5
chemokine (C-X-C motif) ligand 3
poly (ADP-ribose) polymerase family, member 9
interferon-induced protein 44-like
protein kinase D2
interferon induced with helicase C domain 1
interferon stimulated exonuclease gene 20kDa
leukemia inhibitory factor (cholinergic differentiation
factor)
interferon regulatory factor 7
perforin 1 (pore forming protein),
solute carrier family 38, member 5
transmembrane 4 L six family member 1
complement factor B
RAS guanyl releasing protein 3 (calcium and DAGregulated)
solute carrier family 4, sodium bicarbonate transporter,
member 10
guanine nucleotide binding protein (G protein), gamma 2
amphiregulin
protein phosphatase, Mg2+/Mn2+ dependent, 1K
amphiregulin
myxovirus (influenza virus) resistance 2 (similar to mouse)
epithelial stromal interaction 1 (breast)
apolipoprotein L, 1
thioredoxin (TXN
cyclin A1 (CCNA1), transcript variant 1,
epiregulin
Mov10, Moloney leukemia virus 10, homolog (similar to
mouse)
poly (ADP-ribose) polymerase family, member 14
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
cytidine monophosphate (UMP-CMP) kinase 2,
mitochondrial
regulator of G-protein signaling 1
tudor domain containing 7
chemokine (C-C motif) ligand 3
2'-5'-oligoadenylate synthetase-like
transmembrane protein 140
2'-5'-oligoadenylate synthetase 2, 69/71kDa
sapiens schlafen family member 12-like
promyelocytic leukemia
folliculin interacting protein 2
dual specificity phosphatase 5
signal transducing adaptor family member 1
chemokine (C-C motif) ligand 20
lysosomal-associated membrane protein 3
CCR4 carbon catabolite repression 4-like (S. cerevisiae)
cholinergic receptor, nicotinic, alpha 6
tumor necrosis factor receptor superfamily, member 9

2.5 – 3.2
2.5 – 5.1
2.5 – 5.4
2.5 – 3.9
2.4 – 2.5
2.4 – 8.5
2.4 – 4.0
2.4 – 4.1
2.4 – 3.3
2.4 – 5.4
2.4 – 9.6
2.3 – 2.1
2.3 – 5.8
2.3 – 2.9
2.1 – 2.3
2.3 – 2.5
2.1 – 2.3
2.3 – 2.9
2.3 – 4.7
2.3 – 9.1
2.3 – 4.0
2.3 – 3.4
2.3 – 2.5
2.2 – 3.6
2.2 – 3.3
2.2 – 4.1
2.2 – 4.7
2.2 – 7.0
2.2 – 3.4
2.2 – 6.2
2.2 – 3.5
2.2 – 3.9
2.2 – 2.6
2.2 – 3.7
2.1 – 6.6
2.1 – 7.8
2.1 – 2.9
2.1 – 4.2
2.1 – 4.3
2.1 – 3.9
2.1 – 2.4
2.1 – 4.3
2.0 – 2.1
2.1 – 3.3
2.1 – 4.6
2.1 – 2.6
2.1 – 4.4
2.0 – 12.0
2.0 – 4.2
2.0 – 3.8
2.0 – 3.3
2.0 – 3.2
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Table 2.2: Down-regulated Genes in Human PBMC in response to an Aqueous GS
Extract
Rank

Gene
Symbol

NCBI Reference
Sequence ID

Description

1
2
3
4
5
6
7

FPR3
GAPT
CCR2
CSF1R
STEAP4
VCAN
LILRA2

NM_002030
NM_152687
NM_001123396
NM_005211
NM_024636
NM_004385
NM_001130917

8
9

TGFBI
LILRA1

NM_000358
NM_006863

10
11
12
13
14
15
16
17
18

CCR2
CCR1
CCL24
LRRC25
FN1
PLXDC2
CD14
MPEG1
LILRB1

NM_001123041
NM_001295
NM_002991
NM_145256
NM_212482
NM_032812
NM_000591
NM_001039396
NM_006669

19
20
21
22
23
24
25
26
27
28
29
30
31

PECAM1
SLC8A1
PPARG
CTNND1
HMOX1
MIR223
TNS1
CMKLR1
C17orf60
CXCL16
ENG
GPNMB
MAFB

NM_000442
NM_021097
NM_138712
NM_001085458
NM_002133
NR_029637
NM_022648
NM_001142343
NM_001085423
NM_022059
NM_000118
NM_001005340
NM_005461

32
33
34
35
36
37
38
39
40
41
42
43
44

IFI30
SIGLEC10
FAM198B
ARHGAP18
CFP
CD300E
VNN2
TM6SF1
PLXNB2
NLRP12
CX3CR1
HIP1
SLC37A2

NM_006332
NM_033130
NM_001128424
NM_033515
NM_002621
NM_181449
NM_004665
NM_023003
NM_012401
NM_144687
NM_001337
NM_005338
NM_198277

45
46
47
48

CYP27A1
KIAA1598
KIAA1539
EEPD1

NM_000784
NM_001127211
BC004406
NM_030636

formyl peptide receptor 3
GRB2-binding adaptor protein, transmembrane
chemokine (C-C motif) receptor 2
colony stimulating factor 1 receptor
STEAP family member 4
versican (VCAN), transcript variant 1,
leukocyte immunoglobulin-like receptor, subfamily A (with TM
domain), member 2
transforming growth factor, beta-induced, 68kDa
leukocyte immunoglobulin-like receptor, subfamily A (with TM
domain), member 1
chemokine (C-C motif) receptor 2
chemokine (C-C motif) receptor 1
chemokine (C-C motif) ligand 24
leucine rich repeat containing 25
fibronectin 1 (FN1), transcript variant 1
plexin domain containing 2
CD14 molecule (CD14), transcript variant 1
macrophage expressed 1
leukocyte immunoglobulin-like receptor, subfamily B (with TM
and ITIM domains), member 1
platelet/endothelial cell adhesion molecule
solute carrier family 8 (sodium/calcium exchanger), member 1
peroxisome proliferator-activated receptor gamma
catenin (cadherin-associated protein), delta 1
heme oxygenase (decycling) 1
microRNA 223, microRNA
tensin 1
chemokine-like receptor 1
chromosome 17 open reading frame 60
chemokine (C-X-C motif) ligand 16
endoglin (ENG), transcript variant 2
glycoprotein (transmembrane) nmb
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B
(avian)
interferon, gamma-inducible protein 30
sialic acid binding Ig-like lectin 10
family with sequence similarity 198, member B
Rho GTPase activating protein 18
complement factor properdin (CFP
CD300e molecule
vanin 2, transcript variant 1
transmembrane 6 uperfamily member 1
plexin B2
NLR family, pyrin domain containing 12
chemokine (C-X3-C motif) receptor 1
huntingtin interacting protein 1
solute carrier family 37 (glycerol-3- phosphate transporter),
member 2
cytochrome P450, family 27, subfamily A, polypeptide 1
KIAA1598, transcript variant 1
KIAA1539 (cDNA clone MGC:10998 IMAGE:3)
endonuclease/exonuclease/phosphatase family domain containing
1

Fold Change
Range of
Downregulation
-13.4 – -10.8
-6.3 – -5.3
-7.0 – -6.2
-18.3 – -6.1
-6.0 – -3.8
-13.8 – -5.9
-5.2 – -4.6
-4.9 – -4.8
-4.6 – -3.7
-5.4 – -4.1
-3.8 – -2.7
-6.3 – -3.4
-3.6 – -3.5
-4.4 – -3.6
-3.6 – -3.0
-4.2 – -3.3
-3.3 – -2.5
-3.0 – -2.8
-4.5 – -3.0
-3.2 – -2.9
-3.3 – -2.7
-2.7 – -2.3
-3.4 – -2.7
-2.7 – -2.3
-7.1 – -2.7
-2.7 - -2.6
-2.6 – -2.5
-2.6 – -2.5
-4.2 – -2.6
-9.9 – -2.6
-2.7 – -2.5
-2.5 – -2.4
-2.5 – -2.2
-2.4 – -2.1
-2.7 – -2.4
-2.9 – -2.4
-2.6 – -2.4
-2.8 – -2.4
-2.4 – -2.3
-3.6 – -2.3
-5.3 – -2.3
-2.7 – -2.3
-3.1 – -2.3
-5.0 – -2.3
-6.3 – -2.2
-2.4 – -2.2
2-.1 – -2.0
-4.4 – -2.1
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49
50

CD300C
SERPINE1

NM_006678
NM_000602

51
52
53

QSOX1
GLUL
CD9

NM_002826
NM_002065
NM_001769

CD300c molecule
serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1
quiescin Q6 sulfhydryl oxidase 1
glutamate-ammonia ligase
CD9 molecule

-2.1 – -2.1
-3.0 – -2.1
-2.5 – -2.2
-2.2 – -2.0
-2.4 – -2.0

2.5.3 The immunomodulatory effects of North American GS extracts
are mediated by polysaccharides with a molecular weight higher
than 100 kDa.
Once we had determined the transcriptional profile induced by an aqueous North
American GS extract, we proceeded to narrow down the identity of the compounds
involved in this effect. To do this, whole aqueous and polysaccharide GS extracts were
fractioned based on molecular weight. PBMC were then treated with different molecular
weight fractions or fractioned extracts to determine the cytokine production induced by
each fraction. We found that the profile of cytokine production, induced by whole
aqueous or polysaccharide extracts was recapitulated when cells were stimulated with
fractions containing compounds with a molecular weight greater than 100 kDa (Fig. 2.8A
and 2.8B). The 0-10, 10-30, 30-50 and 50-100 kDa fractions produced significantly less
(P < 0.01) IL-6 than the whole aqueous or polysaccharide extracts and the greater than
100 kDa fraction.
Consistent with these results, the greater than 100 kDa fraction of the aqueous GS
extracts (Fig. 2.9A) and of the polysaccharide GS extracts (Fig. 2.9B) had similar
properties as the whole extract, failing to change the response to LPS (data not shown),
but significantly (P < 0.001) decreasing the IL-2 production in response to SEE by
PBMC. Together, these data suggest that the active immunomodulatory component of GS
extracts is a water-soluble polysaccharide of high molecular weight.
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Figure 2.5
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Figure 2.5. – IL-12, IL-23 and IFN-γ responses of PBMC to different GS extracts
and COLD-FX. Human PBMC were stimulated with 150 µg/mL of aqueous,
polysaccharide and ethanol GS extracts or COLD-FX, 100 ng/mL of LPS) or 50 ng/mL
of PMA and 1mg/mL of ionomycin. IL-12p40, IL-12p70, IL-23 and IFN-γ accumulation
in culture supernatants was measured by ELISA. Data represent mean and standard
deviation of 3 independent experiments. Differences between cytokine production of
control, COLD-FX and GS extracts was determined by one-way ANOVA, **: P < 0.01,
***: P < 0.001.
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Figure 2.6
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Figure 2.6. – Aqueous GS extract decreases surface CD-14 expression. Human
PBMC were stimulated for 4 hours with 200 µg/mL of aqueous extract (A) or COLDFX (B). CD-14 expression was measured by flow cytometry using an isotype control
(shaded histogram), no treatment (continuous line histogram in A and B), or treated with
aqueous extract (dashed line histogram in A) or COLD-FX (dashed line histogram in
B). Data represent mean and standard deviation of triplicates. Differences between
responses to control and aqueous GS extract or COLD-FX were significant as
determined by one-way ANOVA (P < 0.05).
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Figure 2.7
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Figure 2.7. – Ingenuity Pathway Analysis of the top 20 up-regulated genes after
exposure to an aqueous GS extract. Shaded molecules indicate the genes that were
directly up-regulated in response to aqueous extract. Unshaded molecules indicate genes
inferred to be up-regulated upon treatment with aqueous extract.
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Figure 2.8
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Figure 2.8. – The immunomodulatory properties of aqueous and polysaccharide GS
extracts are mediated by compounds with a molecular weight higher than 100 kDa.
Human PBMCs were stimulated with increasing concentrations of fractionated aqueous
extract (A) or polysaccharide extract (B) of MWs < 10 kDa (

), 10 - 30 kDa (▲), 30 -

50 kDa (▼), 50 - 100 kDa ( ) and > 100 kDa (●) or whole extracts (

) for 20h. IL-6

concentration in culture supernatants was measured by ELISA. Data represent mean and
standard deviation of triplicates and are representative of 2 independent experiments. **:
P < 0.01; ***: P < 0.001.
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Figure 2.9
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Figure 2.9. – The “molecular weight greater than 100 kDa” fraction of aqueous and
polysaccharide GS extracts recapitulate immunomodulation of T cells responses by
aqueous and polysaccharide GS extracts. Human PBMC were stimulated with 0.1
ng/mL of SEE in the absence or presence of 25 µg/mL of fractionated or whole aqueous
extracts (A) or fractionated or whole polysaccharide extracts (B). IL-2 concentration in
culture supernatants was measured by ELISA. Differences between responses to fractions
or whole extract were significantly different from SEE alone as determined by one-way
ANOVA *: P < 0.05, **: P < 0.01, ***:P < 0.001.
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2.6 Discussion
In this paper, we report that high molecular weight polysaccharides within aqueous North
American GS extracts have significant immunomodulatory properties characterized by
the induction of pro-inflammatory cytokines along a Th1 profile. Such a response results
from broad transcriptional imprinting for immunomodulation. Based on bioinformatics
analysis, North American GS immunomodulation is likely mediated by MAPK (ERK
1/2), PI3K, p38 and NF-κB signalling, that leads to broad cytokine production including
IL-6, IL-2, IL-1β, TNF-α, IFN-γ, IL-12 and IL-23. To our knowledge this work is the
first to report the transcriptional profile of primary human immune cells in response to an
aqueous North American GS extract.
The molecules responsible for the immunomodulatory effects of GS have long been
thought to be the low molecular weight steroidal saponins called ginsenosides

2, 3, 10, 21

.

However, it has been recently shown that polysaccharides in GS may also play a role 5, 1114

. Based on previous studies, the aqueous extract of GS contains a complex mixture of

water-soluble components
polysaccharides

18, 22

including polyacetylenic alcohols,

ginsenosides

and

while the polysaccharide extract contains only the polysaccharides

present in the aqueous extract. Fractionation of the aqueous or polysaccharide extracts by
molecular weight allowed us to link immunomodulation with the high molecular weight
fraction of GS. This fraction contains a complex mixture of polysaccharides with
molecular weights greater than 100 kDa

23

. In contrast, fractions containing

polysaccharides of molecular weight less than 100 kDa had little immunomodulatory
effects. These low molecular weight fractions likely contained ginsenosides as they have
molecular weights between 5 and 15 kDa

24

. Together, this reinforces the idea that

immunomodulation is not primarily induced by ginsenosides.
One interesting finding from this work is that the immunomodulatory properties of
polysaccharides within North American GS extracts are not recapitulated by COLD-FX®,
a preparation that contains 80% of poly-furanosyl-pyranosyl-saccharides from North
American GS

15

. COLD-FX® induced less cytokine production by PBMC and had less

effect on the IL-2 response of T cells stimulated with SEE than either the aqueous or
polysaccharide extracts. It is possible that it is the complex mix of polysaccharides found
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in the aqueous and polysaccharide GS extracts that have a broader profile of effects by
acting on more cell types than COLD-FX®. This is suggested by the observation that the
response to COLD-FX® was similar between both CD14+ and CD14+CD16+ isolated
monocytes and PBMC. However, the response of monocytes to GS extracts was only half
of the response observed with PBMC. While poly-furanosyl-pyranosyl-saccharides in
COLD-FX® show immunomodulatory properties, there are other polysaccharides from
GS that have shown immune effects, including panaxans, ginsan
rhamnogalacturonan II
22

27

25

, arabinogalactans

26

,

, galactose, arabinose, rhamnose, glucose, fucose and mannose

. While the evidence points to a complex mixture of polysaccharides isolated from

North American GS to be the active immunomodulatory compounds, further work is
necessary to better understand exactly which polysaccharides and in what proportions
may be most beneficial for immune modulation.
The mechanism of action of GS polysaccharides is unknown. Many plant polysaccharides
and phenols have been shown to bind to CD14 and TLR-4 28, 29 but this may be secondary
to the presence of LPS. Of interest, CD14 was one of the molecules identified by our
microarray experiments as being down-regulated in response to GS treatment, a result
confirmed by flow cytometry. CD14 is a GPI-anchored membrane protein that acts as the
main receptor for LPS together with TLR-4 and MD2

30

. Down-regulation of surface

CD14 may indicate modulation of this receptor upon interaction with GS or could be a
secondary event following exposure to GS. Our data suggest mostly the latter, occurring
at the transcriptional level. In any case, this effect is not sufficient in vitro to decrease the
response to LPS.
Network analysis to determine the signalling pathways most perturbed by GS extracts
suggested that the GS-induced immune modulation occurs through activation of the NFκB, PI3K, p38 and MAPK (ERK1/2) signalling pathways. These pathways are involved
in the production of pro-inflammatory cytokines 31-33 and have previously been shown to
be induced by GS extract stimulation in PBMC

34

. In addition, these pathways are also

involved in other biological activities of GS such as decreasing ischemic reperfusion
injury 35, killing of tumours 36, 37 and reducing damage from oxidative stress 35. Similarly,
PI3K signalling after GS treatment has been linked to the decrease of ischemic
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reperfusion injury

5, 38

as well as to glucose uptake

39, 40

. Activation of p38 and MAPK

after treatment with GS has been implicated in inhibiting angiogenesis in human
endothelial cells

41

as well as causing preferential apoptosis to cancer cells 42. Therefore,

there seems to be a commonality of signalling events triggered by GS across different cell
types.
Among the genes up-regulated by GS, IFN-γ is the top one, coding for the primordial Th1
cytokine IFN-γ. Of interest, while the IL-2 response of peripheral blood T cells to SEE
was reduced by GS, the IFN-γ response was not. This suggests that the IFN-γ response
induced by GS extracts may come from sources other than activated T cells, likely NK
cells. In this context, induction of a Th1 profile of immunity supports the claim to use GS
extracts to combat respiratory viral infections, as it would enhance cellular immunity.
It is important to note that the pro-inflammatory effect of GS extracts balanced with the
induction of IL-10, an anti-inflammatory cytokine. Production of IL-10 may counteract
the pro-inflammatory Th1 profile, and explain the findings of other groups that have
reported a humoral Th2 response to GS exposure

23, 43

. The magnitude of the IL-10

response varies between extracts and this may explain the differences among reports.
In summary, we show here that a complex mixture of high molecular weight
polysaccharides present in water-soluble extracts of GS mediate most of the
immunomodulatory properties of North American GS. These properties include the
induction of a pro-inflammatory Th1 cytokine production profile and IL-10. This profile
of response is determined by a strong immunomodulatory transcriptional signature
secondary to signalling through the MAPK (ERK 1/2), PI3K, p38 and NF-κB pathways.
Our work thus provides a comprehensive model for the immunomodulatory effects of
North American GS extracts on primary human immune cells.
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3

Biologically Active Ginsenosides Antagonize the
Immunomodulatory Effects of North American Ginseng (Panax
quinquefolius) Aqueous Extracts

3.1 Statement of Contribution
This manuscript will be submitted with authorship as follows, Holly R. Lemmon, Luan
Chau, Dong-Shan An, Song-Gun Kim and Joaquín Madrenas. As first author my
scientific contributions to this manuscript were completing all the experimental data
contained in this manuscript. I also wrote the manuscript in full.

3.2 Abstract
Since its discovery, ginseng (GS) has been used in traditional Chinese medicine and has
been claimed to have many benefits such as immune-enhancing properties. Historically,
it has been proposed that ginsenosides, unique triterpenoid saponin molecules found only
in ginseng, are responsible for GS’s immunomodulatory properties. Here we report that
11 physiologically active ginsenosides and two ginsenoside mixtures by themselves
induced little to no production of pro-inflammatory cytokines IL-6 and IL-1β in human
PBMC. We also show that these ginsenosides antagonized the response of peripheral
blood mononuclear cells (PBMC) to LPS by up to 32%. More importantly, the majority
of these ginsenosides antagonized the immune activating effect of an aqueous GS extract
and the modulatory activity of these extracts on the response to LPS and staphylococcal
enterotoxin. Based on our results, we conclude that physiologically active ginsenosides
have limited immunomodulatory capacity and, in fact, they can act as antagonists of the
immune modulatory properties of North American GS aqueous extracts. Our results may
provide an explanation for the paradoxical effects of GS in the literature due to the
presence of different amounts of ginsenosides in the total GS extracts. These results may
also assist in the optimization of GS preparations with maximum immunomodulatory
properties.
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3.3 Introduction
The ginseng (GS) root has been used for thousands of years in traditional Chinese
medicine and continues to play an important role in Asian culture. GS has been claimed
to have many beneficial health effects including immune enhancement

1, 2

. For this

reason, GS has held its historic position in traditional Chinese medicine and is still widely
used across Asia today. The use of GS is growing in North America. As of 2002,
approximately 13 million men and women reported using GS 3, being the second-highest
grossing herbal supplement in North America 4.
Ginsenosides, low molecular weight saponins unique to the Panax genus of GS plants,
including Asian (Panax ginseng) and North American (Panax quinquefolius) GS

5, 6

, are

one of the compounds found in GS. The two most common groups of ginsenosides are
the protopanaxadiol and protopanaxatriol ginsenosides, each having a unique 4-trans ring
steroidal backbone and differing in the type and location of sugars attached to the
backbone 4. In protopanaxadiol ginsenosides, sugar moieties are attached to the β-OH at
carbon 3 and/or carbon 20. Protopanaxatriol ginsenosides have sugars attached to the αOH at carbon 6 and/or the β-OH at carbon 20 7. The differential addition of different
sugar side chains has resulted in the presence of over 100 unique ginsenosides. Upon
ingestion, ginsenosides are deglycosylated by intestinal bacteria such as Bacteroides sp. 8,
Bifidobacterium sp. 9, Bifidobacterium breve
9

10

, Fusobacterium sp.

11

, Lactobacillus

9

delbrueckii , and Leuconostoc paramesenterioides and these deglycosylated forms are
the biologically active ginsenosides.
The majority of research on the biological effects of GS has focused on ginsenosides and
their metabolites as the molecules responsible for many of the functions ascribed to GS,
including regulation of blood sugar, immunomodulation, anti-tumor effects and
oxidative-stress prevention qualities

2, 12

. For example, protopanaxatriol ginsenosides Re

and Rg1 have been shown to increase the release of nitric oxide from endothelial cells 13.
Compound K (C-K), a major metabolite of ginsenosides has been shown to stimulate
insulin secretion and prevent the destruction of pancreatic islet cells

14

. Also, Rh2 has

been shown to inhibit tumour growth and induced tumour cells to undergo apoptosis

15

.
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However, no single study has assessed such a large number of different ginsenosides
under the same conditions, and in their physiologically active form.
In addition to ginsenosides, polysaccharides have also been proposed to have
immunomodulatory properties. Polysaccharides isolated from ginseng have been shown
to increase Th1 immune responses

16

and duration of the common cold

, inhibit tumour growth

18

17

and decrease the severity

. Previous research has also shown that aqueous

extracts of North American GS, which have both polysaccharides and ginsenosides, as
well as polysaccharide extracts containing only polysaccharides isolated from the
aqueous extract induce pro-inflammatory cytokine production

19

. The aqueous and

polysaccharide North American GS extracts have been shown to induce significant levels
of IL-6, IL-1β and TNF-α as well as IL-10 as compared to the ethanol extract, composed
mainly of ginsenosides

20

. Also, the aqueous and polysaccharide GS extracts decreased

IL-2 production by PBMC stimulated with superantigen, while the ethanol GS extract
had no effect on IL-2 production by PBMC in the same treatment condition 20. Therefore,
we wanted to determine the immunomodulatory effects of ginsenosides alone and in the
presence of polysaccharides of GS.
To

examine

the

effects

of

purified,

biologically

active

ginsenosides

on

immunomodulation, 11 single ginsenosides and two defined combinations of
ginsenosides were tested in human peripheral blood mononuclear cells (PBMC). The
immunomodulatory profile induced by these ginsenosides was established by examining
their capacity to induce pro-inflammatory cytokines as well as their effect on the innate
immune response to LPS and the adaptive T cell response to SEE. We also determined
the properties of biologically active ginsenosides on the effect of North American GS
aqueous or polysaccharide extracts on the innate and adaptive immune responses. We
show that while ginsenosides did not induce high levels of cytokine production, they
antagonized the induction of pro-inflammatory cytokines by the aqueous North American
GS extract and down-regulated the innate immune response to LPS. However, these
compounds did not antagonize the induction of pro-inflammatory cytokines by the
polysaccharide GS extract. Furthermore, biologically active ginsenosides antagonized the
effects of GS extracts on the immune responses to LPS and bacterial superantigens. The
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profile of antagonism of biologically active ginsenosides on GS extracts suggests the
presence of a common mechanistic step for these two projections and their
immunomodulatory effects.

3.4 Materials and Methods
3.4.1 Cells
Blood from healthy volunteers was used. Informed consent from all individuals was
obtained in compliance with the Office of Research Ethics at the University of Western
Ontario. Density gradient centrifugation with Ficoll-Hystopaque was used to isolate
human PBMC. Cells were cultured in RPMI-1640, supplemented with 10% FCS, 1% Lglutamine, 1% penicillin/streptomycin, 1% MEM non essential amino acids, 1% 1M
Hepes and 1% sodium pyruvate.

3.4.2 Preparation of Korean ginsenosides
Ginsenosides Rb1, Rb2, Rc and Rd were purchased from Hongjiu Biotech Co., Ltd.
Ginsenosides C-Mc1, C-K, C-Mc, C-O, C-Y, F2, Protopanaxadiol type (PPD), Rg3, Rh2,
Gypenoside XVII (pure) (Gyp XVII), Gyp XVII (mixture), Gypenoside LXXV (pure)
(Gyp LXXV) and Gyp LXXV (mixture) were prepared from Rb1, Rb2, Rh2 and Rd after
digestion using Terrabacter sp. Gsoil 3082 β-glucosidase, Rhodanobacter sp. Gsoil 3054
β-glucosidase, Rhodanobacter sp Gsoil 3054 α-arabinofuranosidase. As previously
described, enzymatic reactions removed glucose(s) from carbon 3 to produce many
different ginsenosides 21. Gyp XVII (mixture) is composed of Gyp XVII (pure), C-O, CMc1 and F2. Gyp LXXV (mixture) is composed of Gyp LXXV (pure), C-Y, C-Mc and
C-K.

3.4.3 Preparation of North American GS extracts
Roots of Panax quinquefolius were collected from a farm in Southwestern Ontario,
Canada and extracts were prepared as previously described

20

. The sample was ground

and soaked three times for five hours in water at 40 °C. The solution was then filtered
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and excess solvent was removed in a rotavaporizer under vacuum at 45 °C. Powdered
aqueous extract (10 g) was dissolved in 10 mL of distilled water. Four volumes of 95%
ethanol were added to the solution in order to precipitate crude polysaccharides.
Polysaccharide precipitate was collected by centrifugation (3000 rpm for 10 minutes) and
freeze-dried at reduced pressure. The crude polysaccharide (1 g) was re-dissolved in
distilled water (10 mL) and treated with Sevag reagent (1:4 n-butanol:chloroform, v/v, 40
mL) to remove proteins. After precipitation by ethanol and freeze-drying, the final
polysaccharide fraction was obtained. LPS contamination of GS extracts was ruled out by
the Limulus test and treatment with Polymyxin B.

3.4.4 Reagents
SEE was purchased from Toxin Technologies (Sarasota, Florida). LPS from E. coli was
purchased from Sigma-Aldrich (St. Louis, Missouri).

3.4.5 Functional assays
PBMC (2 x 105 cells per well in triplicate and for each experimental group in 200 µL of
media) were stimulated for 20 hours with increasing concentrations of ginsenosides and a
single concentration of aqueous or polysaccharide GS extracts by themselves or in the
presence of LPS or SEE. Culture supernatants were collected and quantification of IL-1β,
IL-6 and IL-2 was performed using human eBioscience ELISA kits (San Diego, CA).

3.4.6 Statistical Analysis
Using Graphpad Prism (Graphpad Instat Software Inc., San Diego, CA), ANOVA with
post-hoc Bonferroni tests were used to determine statistical significance of differences
among groups. Probability values of P < 0.05 were considered significant.
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3.5 Results
3.5.1 Deglycosylated ginsenosides may induce low pro-inflammatory
cytokine production.
To characterize the immune properties of the different deglycosylated ginsenosides and
ginsenosides mixtures we first measured their ability to induce the secretion of the
prototypical pro-inflammatory cytokines (IL-1β and IL-6) by human PBMC. When
PBMC were stimulated with each of the 13 ginsenosides tested, only three of the 13
ginsenosides tested, C-Y, C-Mc and Gyp LXXV (pure), induced low but significant
production of IL-1β (P < 0.001) (Fig. 3.1). In addition to these three ginsenosides, C-O
and Gyp XVII (Mixture) also induced the production of IL-6 (Figure 3.2). These data
suggest that some deglycosylated ginsenosides may induce the production of low levels
of pro-inflammatory cytokines.

3.5.2 Effect of deglycosylated ginsenosides on innate and adaptive
immune responses of PBMC.
Next, we studied the effects of deglycosylated ginsenosides on the innate immune
response of PBMC to LPS. Exposure of PBMC to LPS induced a significant IL-6
response (over 3700 pg mL-1). This response was partially but significantly (P < 0.001)
inhibited by increasing concentrations of deglycosylated ginsenosides. (Up to 37%
inhibition for some ginsenosides, (e.g.; Gyp LXXV (mixture), Gyp XVII (mixture) and
Gyp LXXV (pure)) (Fig. 3.3). Of interest the modulatory effect of deglycosylated
ginsenosides plateaued at 30-40% inhibition.
To determine the effect of deglycosylated ginsenosides on adaptive immune responses,
we used the T cell response to the Staphylococcal superantigen SEE. IL-2 production was
used as an indicator of T cell activation. As expected, SEE induced a significant IL-2
response of PBMC (Fig 3.4), and the addition of deglycosylated ginsenosides had no
modulatory effect on this response. Together these data suggest that biologically active
ginsenosides can partially inhibit the innate responses but do not affect the adaptive
immune responses of human PBMC.
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Figure 3.1
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Figure 3.1. – IL-1β production by PBMC in response to deglycosylated ginsenosides.
Human PBMC were stimulated with increasing concentrations of the indicated
deglycosylated ginsenosides for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O
( ), C-Y (●) and Gyp LXXV (mixture) ( ), (C) Gyp XVII (mixture) (
(pure) ( ) and Gyp XVII (pure) (

), (D) F2 (

), Gyp LXXV

), PPD ( ), Rg3 ( ) and Rh2 ( ).

Levels of IL-1β in culture supernatants were measured by ELISA. Data represent mean
and standard deviation of three independent experiments performed in triplicate.
Differences between IL-1β production by PBMC treated with 5 µg/mL and 0 µg/mL of
ginsenoside were significantly different as determined by one-way ANOVA ***: (P <
0.001).
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Figure 3.2
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Figure 3.2. – IL-6 production by PBMC in response to deglycosylated ginsenosides.
Human PBMC were stimulated for 20 h with increasing concentrations of the indicated
deglycosylated ginsenosides. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O ( ), C-Y
(●) and Gyp LXXV (mixture) ( ), (C) Gyp XVII (mixture) (
( ) and Gyp XVII (pure) ( ), (D) F2 (

), Gyp LXXV (pure)

), PPD ( ), Rg3 ( ) and Rh2 ( ). Levels of

IL-6 in culture supernatants were measured by ELISA. Data represent mean and standard
deviation of three independent experiments performed in triplicate. Differences between
IL-6 production by PBMC treated with 5 µg/mL and 0 µg/mL of ginsenoside were
significantly different as determined by one-way ANOVA *: (P < 0.05), **: (P < 0.01),
***: (P < 0.001).
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Figure 3.3
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Figure 3.3. – Deglycosylated ginsenosides partially blocked the IL-6 response of
PBMC to LPS. Human PBMC were stimulated with 0.1 ng/mL of LPS and increasing
concentrations of the indicated deglycosylated ginsenoside for 20 h. (A) C-Mc1 ( ), C-K
(▲) and C-Mc (▼), (B) C-O ( ), C-Y (●) and Gyp LXXV (mixture) ( ), (C) Gyp XVII
(mixture) (

), Gyp LXXV (pure) ( ) and Gyp XVII (pure) (

), (D) F2 (

), PPD ( ),

Rg3 ( ) and Rh2 ( ). Levels of IL-6 in culture supernatants were measured by ELISA.
Data represent mean and standard deviation of three independent experiments performed
in triplicate. Differences between responses to LPS and LPS with increasing
concentrations of ginsenoside were significantly different as determined by one-way
ANOVA **: (P < 0.01), ***: (P < 0.001).
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Figure 3.4
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Figure 3.4. – Degylcosylated ginsenosides modulate IL-2 responses of PBMC to SEE.
Human PBMC were stimulated with 0.1 ng/mL of SEE and increasing concentrations of
the indicated deglycosylated ginsenoside for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc
(▼), (B) C-O ( ), C-Y (●) and Gyp LXXV (mixture) ( ), (C) Gyp XVII (mixture)
(

), Gyp LXXV (pure) ( ) and Gyp XVII (pure) (

), (D) F2 (

), PPD ( ), Rg3 ( )

and Rh2 ( ). Levels of IL-2 in culture supernatants were measured by ELISA. Data
represent mean and standard deviation of three independent experiments performed in
triplicate.
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3.5.3 Deglycosylated ginsenosides partially antagonized the PBMC
response to North American GS aqueous extracts but not the
response to polysaccharide extracts.
Given the effect of deglycosylated GS extracts on the PBMC response, we looked at the
effect of these ginsenosides on the PBMC response to aqueous or polysaccharide North
American GS extracts. We and others19 have previously shown that aqueous and
polysaccharide extracts of North American GS, which contain both ginsenosides and
polysaccharides and only polysaccharides respectively, induce pro-inflammatory
cytokine production. However, the polysaccharide extract, which contains only
polysaccharides isolated from the aqueous extract, also induced pro-inflammatory
cytokine production19 and we corroborated this effect for IL-1β (Fig. 3.5 and 3.6). When
PBMC were stimulated with either extract and increasing concentrations of
deglycosylated ginsenoside we observed that the all but Gyp XVII (mixture), Gyp LXXV
(mixture) and Gyp LXXV (pure) partially blocked the IL-1β response induced by the GS
aqueous extract on PBMC (Fig. 3.5). However, the deglycosylated ginsenosides had no
effect on the response to the polysaccharide GS extract (Fig. 3.6).
To corroborate the antagonism of these ginsenosides on the North American GS aqueous
extracts, we tested the effect of these deglycosylated ginsenosides on the enhancement of
the response to LPS by North American GS aqueous extracts. Aqueous North American
GS extracts enhanced the PBMC response to LPS. When the aqueous extract was used
with the degycosylated ginsenosides, the PBMC response to LPS was significantly
decreased (Fig. 3.7). No biologically meaningful antagonism of deglycosylated
ginsenosides on the North American GS polysaccharide extract was observed (Fig. 3.8).
Together these results confirm that biologically active ginsenosides antagonize the
aqueous North American GS extract.
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Figure 3.5
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Figure 3.5. – Deglycosylated ginsenosides antagonize the IL-1β response of PBMC to
North American GS aqueous extracts. Human PBMC were stimulated with 1 µg/mL of
aqueous extract and increasing concentrations of the indicated deglycosylated
ginsenoside for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O ( ), C-Y (●) and
Gyp LXXV (mixture) ( ), (C) Gyp XVII (mixture) (
Gyp XVII (pure) (

), (D) F2 (

), Gyp LXXV (pure) ( ) and

), PPD ( ), Rg3 ( ) and Rh2 ( ). Levels of IL-1β in

culture supernatants were measured by ELISA. Data represent mean and standard
deviation of three independent experiments performed in triplicate. Differences between
responses to aqueous extract and aqueous extract with increasing concentrations of
ginsenoside were significantly different as determined by one-way ANOVA ***: (P <
0.001).
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Figure 3.6
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Figure 3.6. – Deglycosylated ginsenosides do not antagonize the IL-1β response of
PBMC to North American GS polysaccharide extracts. Human PBMC were
stimulated with 1 µg/mL of polysaccharide extract and increasing concentrations of the
indicated deglycosylated ginsenoside for 20 h (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼),
(B) C-O ( ), C-Y (●) and Gyp LXXV (mixture) ( ), (C) Gyp XVII (mixture) (
LXXV (pure) ( ) and Gyp XVII (pure) (

), (D) F2 (

), Gyp

), PPD ( ), Rg3 ( ) and Rh2

( ). Levels of IL-1β in culture supernatants were measured by ELISA. Data represent
mean and standard deviation of three independent experiments performed in triplicate.
Differences between responses to polysaccharide extract and polysaccharide extract with
increasing concentrations of ginsenoside were significantly different as determined by
one-way ANOVA ***: (P < 0.001).
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Figure 3.7
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Figure 3.7. – Deglycosylated ginsenosides antagonized the enhanced IL-6 response of
PBMC mediated by the North American aqueous GS extract and LPS. Human
PBMC were stimulated with 0.1 µg/mL of LPS and either 0.5 µg/mL of the indicated
deglycosylated ginsenoside or 1 µg/mL of an aqueous extract, or both for 20 h. Levels of
IL-6 in culture supernatants were measured by ELISA. Data represent mean and standard
deviation of two independent experiments performed in triplicate. Differences between
responses to LPS and a ginsenoside or LPS, a ginsenoside and an aqueous extract were
significantly different as determined by two-way ANOVA ***: (P < 0.001).
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Figure 3.8
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Figure 3.8. – Deglycosylated ginsenosides did not antagonize the IL-6 response of
PBMC to North American GS polysaccharide extracts and LPS. Human PBMC were
stimulated with 0.1 µg/mL of LPS and either 0.5 µg/mL of the indicated deglycosylated
ginsenoside or 1 µg/mL of a polysaccharide extract, or both for 20 h. Levels of IL-6 in
culture supernatants were measured by ELISA. Data represent mean and standard
deviation of two independent experiments performed in triplicate.
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To further corroborate the antagonism of biologically active ginsenoside on the response
to North American GS extracts, we investigated their effects on the activation of T cells
by SEE. When PBMC were stimulated with SEE, a high IL-2 response was detected (Fig.
3.9). In the presence of the aqueous GS extract there was a decrease in IL-2 production as
we have previously reported 20. Alternatively, when PBMC were treated with SEE in the
presence of the aqueous GS extract and C-Mc1, C-K, C-Mc, C-O, C-Y, Gyp XVII
(mixture), Gyp LXXV (mixture), Gyp XVII (pure), PPD and Rg3 the IL-2 response was
restored to the levels seen with SEE alone (Fig. 3.9). Again, this antagonism was not
observed for the North American GS polysaccharide extract except for Gyp XVII
(mixture and pure) (Fig. 3.10). Together, our data indicate that biologically active
ginsenosides act as an antagonist of the North American GS aqueous extract.
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Figure 3.9
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Figure 3.9. – Deglycosylated ginsenosides antagonize the effect of North American
GS aqueous extracts on the IL-2 response of PBMC. Human PBMC were stimulated
with 10 µg/mL of SEE and either 0.5 µg/mL of an indicated deglycosylated ginsenoside
or 1 µg/mL of an aqueous extract, or both for 20 h. Levels of IL-2 in culture supernatants
were measured by ELISA. Data represent mean and standard deviation of two
independent experiments performed in triplicate. Differences between responses to SEE
and a ginsenosides or SEE, a ginsenoside and an aqueous GS extract were significantly
different as determined by two-way ANOVA *: (P < 0.05), **: (P < 0.01), ***: (P <
0.001).
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Figure 3.10
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Figure 3.10. – Deglycosylated ginsenosides did not antagonize the IL-2 response of
PBMC to North American GS polysaccharide extracts and SEE. Human PBMC were
stimulated with 10 µg/mL of SEE and either 0.5 µg/mL of an indicated deglycosylated
ginsenoside or 1 µg/mL of an polysaccharide extract, or both for 20 h. Levels of IL-2 in
culture supernatants were measured by ELISA. Data represent mean and standard
deviation of three independent experiments performed in triplicate. Differences between
responses to SEE and a ginsenosides or SEE, a ginsenoside and an aqueous GS extract
were significantly different as determined by two-way ANOVA *: (P < 0.05), **: (P <
0.01), ***: (P < 0.001).
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3.6 Discussion
Our study is a comprehensive look at the immunomodulatory capacity of 11 processed
and biologically active pure ginsenosides and two biologically active ginsenoside
mixtures (Gyp LXXV and Gyp XVII). Our results show that these ginsenosides appear to
have minimal pro-inflammatory effects. More importantly they can act as antagonists for
North American GS aqueous extracts, partially blocking the effects of these cytokines on
PBMC and the effects of these extracts on the innate (LPS) and adaptive (superantigen)
immune responses.
Overall, biologically active ginsenosides antagonize the properties of aqueous but not of
polysaccharide GS extracts. The differential antagonism of the two extracts may be due
to the fact that the higher potency of polysaccharides in the polysaccharide extract as
compared to the aqueous extract that also contains ginsenosides and other compounds.
However, based on the data that the aqueous extract can be antagonized by ginsenosides
but the polysaccharide extract cannot be antagonized, leads to the idea that the
antagonism of GS polysaccharide by ginsenosides is an example of competitive
antagonism. This is because competitive antagonism can be overcome by increasing the
concentration of the agonist 22; in this case the GS derived polysaccharides. The degree
of antagonism varies greatly between the different ginsenosides, suggesting that certain
single, highly purified ginsenosides may have a higher affinity for the receptor than other
ginsenosides. Alternatively, the observed antagonism may be due to an antagonistic
effect of signalling molecules downstream of the receptors for ginsenosides and
polysaccharides.
The antagonism revealed here may help to identify the receptors mediating GS immune
effects. One potential candidate for ginsenosides is the glucocorticoid receptor, whose
ligands are the steroid hormones cortisol and other glucocorticoid hormones

23-26

.

However, ginsenosides have also been shown to affect a variety of cell signalling
pathways including the AMPK pathway

27-29

and this may potentially result in

immunomodulation. Despite extensive research, the identification of a ginsenoside
receptor and hence the mechanism of action of ginsenosides remains unknown. Similarly,
the GS polysaccharide receptor and its mechanism of action are also unknown. GS
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polysaccharides have been proposed to use TLR 2 and TLR 4 as receptors to mediate
their effects 30, 31. Future studies may then focus on these and other receptors to assess the
degree of antagonism of ginsenosides or other responses through these receptors.
The antagonistic properties of each ginsenoside varied. This may be in part due to the
structure of the ginsenosides and their ability to interact with their putative receptors.
While the backbone of all ginsenosides is very similar, the attached sugar groups are
what give each ginsenoside its unique properties. These sugar groups may be important
for receptor affinity and could explain the variable effects of different ginsenosides. The
inability to antagonize the polysaccharide GS extract is likely due to differences in the
composition of the aqueous and polysaccharide North American GS extracts. GS extracts
contain three major groups of immunomodulatory compounds: ginsenosides
polysaccharides

30, 34, 35

and polyacetylene compounds

36, 37

15, 32, 33

,

. These three compounds are

present in the unfiltered aqueous GS extract, where there is no treatment to preferentially
remove specific compounds

19

. In contrast, the polysaccharide extract is composed of

only the polysaccharides from the aqueous extract and undergoes significant processing
to remove other contaminants

19

. Therefore, the preferential antagonism of the aqueous

extract may be due to its lower concentration of polysaccharides or the variety of
compounds present.
The work presented here further defines the complex immunomodulatory nature of GS.
Based on our results, we propose that ginsenosides are not the primary
immunomodulatory component of GS. As we have previously shown, the immune
modulatory properties of North American GS extracts are mostly recapitulated by high
molecular weight polysaccharides. Aqueous extracts do contain these polysaccharides.
The observation repeated here mostly that aqueous preparations of North American GS
may have lower effects due to a high content of ginsenosides. In contract polysaccharide
preparations may be more clinically beneficial and not susceptible to antagonism.
In conclusion, we show that biologically active ginsenosides act as antagonists of North
American GS aqueous extracts. These results may be important to optimize the use of
North American GS preparations tailors to specific immune modulatory properties.
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4

Discussion

4.1 Overview of Experimental Results
4.1.1 Specific Aim One: To establish the effects of ginseng extracts on
innate and adaptive immune responses of human PBMC.
To investigate the immunomodulatory effects of North American ginseng extracts on
human PBMC, induction of pro-inflammatory (IL-6, IL-1β, TNF-α) and antiinflammatory (IL-10) cytokines were used as readouts. Treatment of PBMC with the
aqueous and polysaccharide ginseng extracts as well as COLD-FX® resulted in
significant up-regulation of the aforementioned cytokines, when compared to cytokine
induction by the ethanol ginseng extract.

All cytokines were produced in a dose-

dependent manner. In order to ensure that the observed cytokine production was not
unique to the ginseng produced at a single farm, the three different ginseng extracts were
produced from ginseng harvested from seven different farms across south western
Ontario to determine cytokine production. Similar trends were observed between the
extracts of all seven farms. Ginseng aqueous and polysaccharide extracts as well as
COLD-FX® induce complex immune responses characterized by significant induction of
pro-inflammatory cytokines but also the induction of the anti-inflammatory cytokine IL10. The differential production of these cytokines by the three different North American
ginseng extracts may be due to the quantities of the major immunomodulatory
compounds in each of the extracts. It appears that extracts that contain high
concentrations of ginseng polysaccharides (e.g. the aqueous and polysaccharide extracts)
induced higher cytokine production than the highly ginsenoside based ethanol extract.
Polymyxin B treatment of the aqueous, polysaccharide and ethanol ginseng extracts, as
well as COLD-FX®, was used to determine if the extracts were contaminated with LPS.
Polymyxin B treatment did not affect the induction of pro-inflammatory cytokine
production by ginseng extracts. Therefore, the induction of pro-inflammatory cytokines
was based on components of the ginseng extracts and not LPS contamination.
To determine the IL-6 contribution of monocytes to the total amount of IL-6 produced by
PBMC, two monocyte subsets were isolated. CD14+ and CD14+CD16+ monocytes, were

112

isolated from PBMC and treated with the aqueous or polysaccharide ginseng extracts or
COLD-FX®. There was no significant difference in IL-6 production of the two monocyte
populations after treatment with the aqueous or polysaccharide ginseng extracts or
COLD-FX®. However, there was a significant difference in the IL-6 production of PBMC
when compared to CD14+ and CD14+CD16+ monocytes treated with the aqueous and
polysaccharide ginseng extracts. The difference in IL-6 production between PBMC and
the two isolated monocyte populations was not significantly different when treated with
COLD-FX®. Therefore, the complex mixture of polysaccharides present in the aqueous
and polysaccharide extracts is able to activate multiple cell types including monocytes.
While the single polysaccharide family present in COLD-FX® only activates monocytes
to produce IL-6.
To characterize the effects of ginseng extracts and COLD-FX® on the innate immune
system, LPS stimulation was used. None of the aqueous, polysaccharide or ethanol
ginseng extracts nor COLD-FX® had an effect on the induction of IL-6 in response to
LPS. This trend was observed across different concentrations of LPS as well as ginseng
extracts and COLD-FX® and therefore it is not likely to be due to a saturation of the
responses.
In order to further characterize the effect of ginseng extracts on immune responses, the
adaptive T cell response to SEE was used. PBMC treated with SEE and the aqueous or
polysaccharide ginseng extracts significantly decreased IL-2 production compared to
PBMC treated with SEE. The ethanol ginseng extract and COLD-FX® however, did not
significantly change the SEE induced IL-2 production of PBMC. These trends were again
observed under a variety of concentrations of extracts, COLD-FX® and SEE. Based on
our results it appears that North American ginseng aqueous and polysaccharide extracts
as well as COLD-FX® decreased the adaptive immune response to SEE, while having no
effect on innate immune responses to LPS.
The results reported in this aim were consistent across the seven different ginseng farms
tested. Upon confirmation of these results, only ginseng extracts from farm 3 were used
in further investigations.

113

4.1.2 Specific Aim Two: To define the transcriptional profile induced
by the aqueous ginseng extract.
In order to determine the transcriptional profile of PBMC treated with the aqueous
ginseng extract, microarray analysis was performed for two independent donors. After
exclusion of genes with less than a two-fold change in mRNA expression as compared to
unstimulated PBMC, 104 genes were commonly up regulated and 53 genes were downregulated. A bioinformatics analysis of these genes revealed a transcriptional profile of
immunomodulation. Specifically, IFN-γ gene was the most up-regulated gene, coding for
the primary Th1 cytokine. Formyl peptide receptor 3 (FPR3) was the most downregulated gene. A large number of the regulated genes coded for chemokines, cytokines
or were genes required for proper immune function. These results were replicated in
genetically unrelated donors. In order to compare the modulation of genes in each donor,
heat mapping was used. There were strong similarities in heat map profiles between these
donors, indicating that the profile of immunomodulation was similar in both donors.
To determine the effects of modulating the top 20 up-regulated genes, Ingenuity Pathway
Analysis (IPA) was used. IPA uses software to determine the biological pathways most
perturbed by these genes forming a network of interactions. In doing this, there was
strong inferred modulation of the MAPK (ERK-1/2), PI3K, p38 and NF-κB pathways in
response to treatment of PBMC with the aqueous ginseng extract. Further analysis of this
network also strongly represents the dominance of cytokines, chemokines, receptors and
signalling pathways involved in a Th1 immune response.
Microarray analysis showed increased transcript levels of IFN-γ, IL-12p40, IL-12p70 and
IL-23 after treatment of PBMC with the aqueous ginseng extract. ELISA was used to
determine the effects of the polysaccharide and ethanol ginseng extracts and COLD-FX®
on the induction of these cytokines by PBMC. The aqueous ginseng extract induced
significant up-regulation of all four cytokines, IFN-γ, IL-12p40, IL-12p70 and IL-23
compared to an un-stimulated control. However, the polysaccharide ginseng extract
induced significant amounts of IFN-γ IL-12p40 and IL-23, as compared to the ethanol
ginseng extract that only produced significant amounts of IL-12p40. COLD-FX® did not
induce production of IFN-γ, IL-12p40, IL-12p70 and IL-23 above levels of the baseline
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control. Alternatively, CD14 was shown in the microarray to be down-regulated by a fold
change of between 3.3 and 4.2. The expression of surface CD14 was significantly down
regulated in PBMC treated with the aqueous ginseng extract and COLD-FX® when
compared to an un-stimulated PBMC control. Expression of CD14 was measured by flow
cytometry.

4.1.3 Specific Aim Three: To perform a preliminary isolation and
characterization of the active immunomodulatory compounds of
ginseng.
The nature of the aqueous and polysaccharide ginseng extracts is that they are composed
of many different compounds, which is especially true for the aqueous extract that
contains both a variety of ginsenosides as well as many polysaccharides. Therefore, in
order to determine which of the many compounds in these extracts were responsible for
the immunomodulatory properties, fractionation of the extracts was required. When the
aqueous and polysaccharide extracts were fractioned based on molecular weight, the only
fraction that recapitulated the induction of IL-6 was the greater than 100 kDa fraction. To
confirm this result all fractions as well as the aqueous and polysaccharide ginseng extract
were tested to compared the effects of the fractions and extracts on the SEE response.
Similar to previous results, only the greater than 100 kDa fraction down-regulated the
SEE induced IL-2 production of PBCM to the same magnitude as the aqueous and
polysaccharide North American extracts.
Ginsenosides, unique saponin molecules found only in some species of ginseng have
historically been known as the active ingredients of ginseng. However, since
ginsenosides have a molecular weight less then 20 kDa, the notion of ginsenosides as the
immunomodulatory compounds of ginseng conflicted with our previous results. To
determine the effects of ginsenosides on immunomodulation, 11 purified, biologically
active ginsenosides and two ginsenoside mixtures were obtained. The majority of these
ginsenosides did not induce IL-1β production in PBMC. Only C-Y, C-Mc and Gyp
LXXV (pure) induced the pro-inflammatory cytokine IL-1β above baseline controls. This
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is compared to almost half of the ginsenosides that induced significant amounts of IL-6
production in PBMC, including C-Y, C-Mc, Gyp LXXV (pure), C-O and Gyp XVII
(mixture).
These 13 ginsenosides were also tested for their immunomodulatory capacity of the LPS
and SEE induced responses of PBMC. PBMC were co-stimulated with each of the
ginsenosides and LPS using IL-6 production as a marker of activation. All 13
ginsenosides tested decreased IL-6 production in response to LPS. However, when
PBMC were stimulated with SEE and each of the ginsenosides there was no biologically
relevant difference in IL-2 production.
Considering the opposing results that ginsenosides decrease the LPS response while the
aqueous extract containing ginsenosides had no effect on the LPS response, there
appeared to be a possible antagonistic effect of the ginsenosides and polysaccharides in
the aqueous extract. To determine if there were any antagonistic effects of
polysaccharides or ginsenosides, PMBC were co-stimulated with ginsenosides and the
aqueous or polysaccharide ginseng extracts. All of the 13 ginsenosides tested antagonized
the induction of IL-1β in PBMC co-treated with the aqueous ginseng extract.
Alternatively, none of the 13 ginsenosides antagonized IL-1β production by PBMC cotreated with the polysaccharide ginseng extract.
The antagonism of the aqueous extract prompted the study of ginsenosides effect on the
response of PBMC treated with the aqueous or polysaccharide ginseng extracts and LPS.
When PBMC were stimulated with LPS, the aqueous ginseng extract and each of the
ginsenosides, all of the ginsenosides significantly decreased IL-6 production in PBMC
except Gyp LXXV (mixture), Gyp XVII (mixture), Gyp LXXV (pure). Similar to
previous data, PBMC treated with LPS, the polysaccharide ginseng extract and each of
the ginsenosides resulted in no significant decrease in IL-6 production when compared to
PBMC treated with LPS and the aqueous ginseng extract.
Finally, the antagonistic effect of ginsenosides on the aqueous and polysaccharide
ginseng extracts was also characterized using the response of PBMC to SEE. When
PMBC were treated with SEE, the aqueous ginseng extract and each of the ginsenosides,
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all of the ginsenosides except Gyp LXXV (pure), F2 and Rh2 resulted in increased IL-2
production when compared to PBMC treated with SEE and the aqueous ginseng extract.
Alternatively, when PBMC were treated with SEE, the polysaccharide ginseng extract
and Gyp XVII (mixture) or Gyp XVII (pure) there was a significant increase in IL-2
production compared to PBMC treated with SEE and the polysaccharide extract. All the
rest of the ginsenosides had no effect on IL-2 production induced by SEE and the
polysaccharide extract. If the ginsenosides are antagonizing the ginseng polysaccharides
in the aqueous extract, than there would be a clinical benefit to using preparations of
single types of ginseng derived compounds based on the desired effect.

4.2 Model of function:
4.2.1 Ginseng induces a Th1 transcriptional profile
Ginseng has been thought to have an immunomodulatory role for hundreds of years but
only recently has this been properly and thoroughly documented. Ginseng has an
immunomodulatory role on human primary cells in vitro, through the induction of a Th1
response as determined by transcriptional profiling. This transcriptional profile is likely
the result of modulation of signals mediated by the MAPK (ERK-1/2), PI3K, p38 and
NF-κB pathways, as compounds of these pathways were among the 20 most up-regulated
genes identified by the microarray analysis. These pathways have been extensively
documented in the literature to be altered in a variety of immunomodulatory effects
including decreasing ischemic reperfusion injury 1-3, tumor killing 4 and preferential
apoptosis of cancer cells 5. Activation of MAPK (ERK-1/2), PI3K, p38 and NF-κB
pathways has also been shown to induce pro-inflammatory cytokines such as IL-6 and
TNF-α that is consistent with previous results from our lab and others 6-8.
CD4+ Th1 cells are characteristically large producers of IFN-γ and are responsible for
activating macrophages and the differentiation of CD8+ T cells into cytotoxic cells.
Transcriptional analysis of PBMC stimulated with the North American aqueous ginseng
extract revealed an up-regulation of IFN-γ mRNA by a fold change between 53.2-55.9
above control. The induction of IFN-γ was also observed at the protein level by the
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aqueous and polysaccharide ginseng extracts. However, when PBMC are co-stimulated
with those extracts and SEE there was a significant decrease in IL-2 production.
Together, these results imply that the production of IFN-γ is likely not coming from T
cells and is instead being secreted by NK cells, the other major producer of IFN-γ.
Furthermore, the induction of Th1 immune responses in general, coupled with the
induction of pro-inflammatory cytokines is likely the mechanism used to induce many of
the reported immune enhancing properties of ginseng extracts and COLD-FX®.
While the evidence for a Th1 immune response induced by North American ginseng
extracts is clear, there are reports in the literature that ginseng also induces of a Th2
response. The reported Th2 immune response is usually based on the observation of
induction of IL-10, IL-4 or IL-5

9-11

. Based on microarray analysis, ginseng extracts did

not affect the regulation of these cytokines by greater than a two-fold change. However,
our results did show an induction of IL-10 at the protein level. This induction of IL-10
may explain why none of the ginseng extracts had an effect on the LPS response, as IL10 is known to suppress macrophage function 12. The presence of IL-10 may also have a
modulatory role in the strong induction of pro-inflammatory cytokines 12.
North American ginseng induces an immunomodulatory affect by altering the
transcriptional profile of susceptible cells resulting in the promotion of a Th1 response.
This response is likely mediated by modulation of the MAPK (ERK-1/2), PI3K, p38 and
NF-κB which induces the characteristic production of IFN-γ and pro-inflammatory
cytokines. The production of IFN-γ is likely by NK cells and results in the activation of
macrophages, and removal of intracellular pathogens and dying cancer cells. Ginseng
also appears to induce an IL-10 response although this was not observed by microarray
analysis and may serve to modulate the strong pro-inflammatory responses observed
through feedback mechanisms.
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4.2.2 High molecular weight polysaccharides are the Active
Immunomodulatory Compounds of Ginseng
The ginseng aqueous extract is a complex mix of ginsenosides and polysaccharides, both
of which have been shown to be immunomodulatory. The polysaccharide ginseng extract
is a purified solution of only the polysaccharides present in the aqueous ginseng extract.
Across all of the bioassays completed, the aqueous and polysaccharide ginseng extracts
induced similar responses. The ethanol extract, which is a ginsenoside rich extract,
appears to have very little if any immunomodulatory capacity. From this it can be
inferred that the polysaccharides in the aqueous extract are the strongest
immunomodulatory compounds in the aqueous ginseng extract.
To further characterize the immunomodulatory compounds of ginseng, differential
fractionation was used to separate the ginsenosides and polysaccharides of the aqueous
and polysaccharide extracts. Ginsenosides are low molecular weight compounds,
typically less than 20 kDa while polysaccharides usually range from 50-150 kDa 13. Only
compounds with a molecular weight greater than 100 kDa induced a similar production
of IL-6 from PBMC as the North American ginseng aqueous or polysaccharide extracts.
These results are consistent with the immunomodulatory compounds being the
polysaccharides and not the ginsenosides.
There is a clear difference between a polysaccharide extract composed of a complex
mixture

of

polysaccharides

and

poly-furanosyl-pyranosyl-saccharides,

a

single

polysaccharide family isolated from an aqueous ginseng extract. COLD-FX®, is
composed

of

over

80%

poly-furanosyl-pyranosyl-saccharides.

Similar

to

the

polysaccharides in the polysaccharide ginseng extract, poly-furanosyl-pyranosylsaccharides are also isolated from a North American aqueous ginseng extract. However,
there is a difference in the modulatory effect of the polysaccharide ginseng extract and
COLD-FX®. For example, when comparing the IL-6 production of CD14+ monocytes,
CD14+CD16+ monocytes and PBMC treated with the aqueous or polysaccharide ginseng
extract, both populations of monocytes produced significantly less IL-6 than PMBC.
However, COLD-FX® induced a similar production of IL-6 regardless of cell type.
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Therefore, the variety of compounds in the polysaccharide extract induces a broader
range of cell populations to secrete the pro-inflammatory cytokine IL-6 than COLD-FX®.
The effects of ginseng on a variety of immune responses has been well characterized in
the literature. However there is complete lack of knowledge on a well defined receptor.
Other plant polysaccharides have been shown to bind to CD14 and TLR-4 14, 15, but there
is no clear evidence whether or not ginseng polysaccharides do as well. Without knowing
the receptor of ginseng polysaccharides, it is difficult to determine why COLD-FX®
appears to stimulate only the monocyte cell population of PBMC, while the
polysaccharide extract stimulates other cell populations also. It could be because the
polysaccharides in the North American polysaccharide ginseng extract are ligands for
multiple receptors, some of which that are not found on monocytes.

4.2.3 The Role of Ginsenosides in Immunomodulation
While ginseng polysaccharides clearly drive the production of pro-inflammatory
cytokines and many other immune responses, it was possible that ginsenosides could also
have an immunomodulatory role. 13 physiologically active ginsenosides were tested for
their ability to induce pro-inflammatory cytokines, their effects on the innate immune
response to LPS and their effects on the adaptive T cell response to SEE. All 13 of the
ginsenosides decreased the production of IL-6 by PBMC in response to LPS stimulation.
These results were contradictory to similar experiments using the ethanol extract, which
is known to contain only ginsenosides

13

. This may be because the ethanol extract is

composed of all of the ginenosides present in the ginseng root and the concentration of
any given ginsenoside depends on its predominance in the root. Therefore, the
concentration of each single ginsenoside in the ethanol extract may be too small to have
an effect on PBMC treated with LPS.
Another difference between the purified ginsenosides and the ethanol extract is that
purified ginsenosides were deglycosylated by bacteria into their active form. This mimics
the conditions of being ingested, processed and absorbed in the gut. Therefore, the
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ginsenosides in the ethanol extract are much larger and contain extra sugar groups which
may alter receptor-binding affinity or prevent receptor binding all together. However, the
effect of the larger sized ginsenosides and the presence of excess sugars on receptor
affinity and binding cannot be determined as there is no known ginsenoside receptor.
Ginsenosides have been proposed to bind the glucocorticoid receptor, however the
evidence is not robust 16-18. Typically, cortisol and other glucocorticoid hormones are the
ligands of the glucocorticoid receptor. However, due to the similar structure of
ginsenosides to these steroid hormones, ginsenosides have also been proposed to bind to
glucocorticoid receptors. The evidence for the glucocorticoid receptor as the receptor for
ginsenosides is weak and further research is required. Ginsenosides have also been shown
to affect the signalling of a variety of signalling pathways including the AMPK pathway
19-21

. This signalling pathway may also be involved in the immunomodulation by

ginsenosides.

4.2.4 Ginsenosides Antagonize the effects of the North American
Ginseng Aqueous Extract
The immunomodulatory roles of ginsenosides and polysaccharides are very different. Our
data indicate that ginsenosides antagonize some of the modulatory effects of
polysaccharides in North American aqueous ginseng extracts. The antagonistic effect of
ginsenosides on the aqueous extract is clear. However, antagonism of the polysaccharide
extract is more dependent on the response and ginsenoside in question. The obvious
difference between the aqueous and polysaccharide extract is their composition. The
polysaccharide extract is composed of only the polysaccharides of the aqueous ginseng
extract, while the aqueous extract contains ginsenosides and other compounds. When
equal concentrations of both extracts are added, PBMC receiving the polysaccharide
extract would be receiving a greater amount of polysaccharide than PBMC treated with
the aqueous extract. Therefore the lack of antagonism by ginsenosides of the
polysaccharide extract may be due to a saturating effect of the polysaccharide.
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The mechanism of the antagonism of ginseng polysaccharides by ginsenosides cannot be
determined without knowing the receptor for both compounds. The receptors may signal
through different biochemical pathways which interact downstream of activation to
inhibit the signalling of one pathway over the other. This is the most likely explanation
for the antagonism, as the antagonism of the aqueous ginseng extract does not appear to
be dose dependent. Thus, it is not likely that ginsenosides and ginseng derived
polysaccharides share a receptor.

4.3 Future directions:
4.3.1 To analyze in depth the microarray results
Microarray analysis of PBMC treated with the aqueous ginseng extract produced 104 upregulated genes and 53 down-regulated genes, each of possible importance to ginseng
immunomodulation. These results provide a complex picture of immunomodulation by
ginseng and are the basis for further investigation. For example, the down-regulation of
TGF-β, an important anti-inflammatory cytokine that plays a role in T cell differentiation
may be important in determining the differentiation of T cells into lineages other then
Th1. TGF-β also induces would healing and scar formation, therefore its down regulation
will inhibit these aspects and may induce chronic inflammation. Thus further study is
required to determine the effects of down-regulating TGF-β in the context of such large
induction of pro-inflammatory cytokine and the effect on chronic inflammation. This will
also be important when considering the context and duration of North American ginseng
use. There is also a series of chemokine receptors and other receptor molecules that have
been identified as being down-regulated by microarray analysis. These receptors may be
valuable in further understanding the exact role of North American ginseng extracts and
purified compounds in cell recruitment and immune responses.
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4.3.2 To identify the receptor of ginsenosides and ginseng
polysaccharides
A major block in the progress of ginseng research is that there is no concrete evidence of
a receptor for the ginsenosides or ginseng polysaccharides. While the glucocortiod
receptor has been proposed as a receptor for ginsenosides, the evidence is not complete.
Identifying a receptor would allow for further understanding of the antagonism of
polysaccharides by ginsenosides, which could be due to cross talk in biochemical
signalling pathways downstream of the receptor.
In order to determine the receptor of ginseng polysaccharides, it is first important to
determine the structure of each of the polysaccharides in the polysaccharide ginseng
extract using nuclear magnetic resonance spectroscopy. Molecular analysis can be done
based on the structure of the ligand polysaccharides to determine possible receptors on
responding cells such as T cells, monocytes and NK cells. Following this, these receptors
could be knocked out using cell lines of specific immune cells, or they could be blocked,
depending on the receptor. If the ginseng receptor is knocked out or blocked successfully
then treatment with the ginseng polysaccharide extract should not induce cytokine
production or changes in any of the signalling pathways of the cell.

4.4 Ginseng in disease:
4.4.1 Ginseng in Cancer
Ginseng has a broad range of effects on many cell-signalling cascades and therefore has
been investigated as an anti-cancer agent. Ginseng treatment of many human cancers
including hepatocellular carcinoma, lung carcinoma, breast cancer and cervical cancer
has been shown to be beneficial

22-25

. For example, ginsenosides have been shown to

decrease tumor invasion and metastasis, decrease tumor weight and volume and inhibit
cell proliferation

22, 24, 26

. In a gastric cancer model, treatment with the ginsenoside C-K

induced apoptosis through a Bid-mediated mitochondrial pathway 27. Similarly, when the
same gastric cancer cells were injected into nude mice, C-K treatment of those mice
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decreased tumor formation

27

. C-K is not the only ginsenoside however to have anti-

cancer effects. Rg3 has been shown to decrease tumor weight and volume by 30% in lung
carcinoma cells

23

. Rh2 also induced mitochondria mediated cell death by the up-

regulation of the pro-apoptotic factors Bak, Bax and Bim while down-regulating the antiapoptotic factors Bcl-2, Bcl-xL and Mcl-1 28. Finally, using human colon cancer cells, an
aqueous ginseng extract as well as its purified ginsenoside and polysaccharide
components all decreased cell proliferation

29

. There appears to be significant evidence

that ginsenosides mediate the apoptosis of cancer cells through mitochondrial mediated
apoptosis 27, 28, 30. Ginsenosides have been shown to arrest cell growth in the G0/G1 phase
29, 31

. These results indicate that purified components of ginseng as well as ginseng

extracts may be a useful tools in the fight against cancer.

4.4.2 Ginseng in Diabetes
Ginseng has been well studied with respect to its hypoglycemic effects with promising
results. There have even been clinical trials completed based on these results, however
the lack of standardization of ginseng has resulted in the failure of such trials.
Nonetheless, ginseng was shown to decrease blood glucose when given 40 minutes prior
to a meal in both control and patients with diabetes mellitus

32

. Ginseng has also been

shown to decrease insulin resistance and fasting blood glucose in diabetes mellitus 33. A
ginseng aqueous extract has also been shown to increase insulin secretion from β cells
and prevent β cell apoptosis

34

. This was proposed to occur through inhibition of the

mitochondrial protein uncoupling protein 2 (UCP-2) which increases ATP and the antiapoptotic factor Bcl-2 34. In addition to modulating UCP-2 and Bcl-2, under high glucose
conditions, ginsenosides Rb1, Rg3 and Rb2 have been shown to decrease the
phosphorylation of JNK, p38 and p42/p44 MAPK resulting in a protective effect against
diabetic nephrology 35. These results show that ginseng plays a complex role in mediating
diabetic β cell apoptosis, as well as moderating blood glucose.
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4.5 Conclusions:
Ginseng was thought to be immunomodulatory for hundreds of years before science
actually provided any evidence to support this claim. However, the majority of ginseng
research has been done using neoplastic cell lines that are not representative of the variety
of cells involved in a human immune response. The work presented in this thesis
provides evidence of immunomodulation in human PBMC by ginseng polysaccharides
and ginsenosides as well as an aqueous and polysaccharide North American ginseng
extracts.
Initially, the induction of pro- and anti-inflammatory cytokines in PBMC by the aqueous
and polysaccharide ginseng extracts was confirmed. There was significantly less cytokine
production induced by the ethanol ginseng extract. This trend was also observed in
response to SEE stimulation of adaptive T cell responses. The aqueous and
polysaccharide ginseng extracts significantly reduced the IL-2 production in PBMC while
the ethanol ginseng extract had no effect on IL-2 production. This immunomodulatory
profile was confirmed at the transcriptional level by microarray analysis. Ginseng induces
its immunomodulatory affects by altering gene transcription in susceptible cells resulting
in a pro-inflammatory Th1 immune response characterized by the induction of IFN-γ.
Finally, we have shown that the modulation of immune responses by ginseng
polysaccharides and ginsenosides is different and that certain ginsenosides can
antagonize polysaccharide-induced responses. Ginsenosides antagonize the induction of
pro-inflammatory cytokines induced by LPS stimulation. They also antagonized the
responses of the aqueous and to a lesser extent the polysaccharide ginseng extracts.
Based on these results, we propose that ginseng induced immunomodulation results in a
Th1 transcriptional signature mediated primarily by ginseng polysaccharide. The Th1
profile is characterized by IFN-γ production by NK cells and the activation of MAPK
(ERK-1/2), PI3K, p38 and NF-κB pathways. This profile is induced by the complex
mixture of ginseng polysaccharides found in the aqueous and polysaccharide ginseng
extracts. However, ginsenosides present in the aqueous extract decrease some of the
immunomodulatory responses. Ginsenosides modulate immune response to LPS and SEE
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in opposing ways as the ginseng polysaccharides. Further work is required to determine
how ginsenosides antagonize the effects of ginseng polysaccharides.
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